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ABSTRACT 
Trans-activation response (TAR) DNA-binding protein 43 (TDP-43) is a natively 
dimeric 414-residue protein that is encoded by the human TARDBP gene that has 
important implications in the pathogenesis of the neurodegenerative disorders ALS, FTD, 
and CTE. TDP-43 has been found hyperphosphorylated and ubiquitinated in the 
aggregates of the affected neurons of these diseases. The discovery of the presence of 
TDP-43 positive inclusions in brain matter of patients with CTE has made repetitive 
brain injury a possible environmental stimulus for aggregation in TDP-43 
proteinopathies. We expand upon the hypothesis that TDP-43 readily aggregates under 
agitation conditions and that the addition of poly-TG repeats to TDP-43 in aggregation 
conditions attenuates its aggregation propensity. We expressed a recombinant S48E 
phosphomimetic mutation of TDP-43 with an N-terminal GFP fluorescent tag in 
Escherichia coli and induced aggregation by agitation. We examined the extent to which 
different DNA/RNAs and differing stoichiometric concentrations of these nucleic acids 
affected the aggregation in vitro. We show that the addition of RNA/DNA to the S48E 
mutant does not have profound effects on aggregation attenuation under in vitro 
aggregation conditions.   
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CHAPTER 1: INTRODUCTION 
 
1. 1 Protein Aggregation and Human Disease 
Cellular proteins are mortal and have cell cycles that are defined by their half-life. 
Two processes, synthesis and degradation, work in synchrony to maintain protein 
concentration in cells. Turnover of cells is physiologically important because intracellular 
levels of proteins should change in response to cellular stimuli during developmental and 
cell cycle processes. A dysfunction in the clearance system leads to accumulation of 
protein that can be toxic to the cell (Rubinsztein, 2006).  Such structural aberrations 
ultimately aggregate either within the cell or extracellularly. Protein aggregates are a 
feature of several human diseases such as neurodegenerative diseases (Ross & Poirier, 
2004), prion diseases (Aguzzi & Calella, 2009), cancer (Yang-hartwich, Bingham, 
Garofalo, Alvero, & Mor, 2015), metabolic diseases (De Baets, Van Doorn, Rousseau, & 
Schymkowitz, 2015), immune disorders (Kumar et al., 2016), and cystic fibrosis (Du et 
al., 2015).  
Misfolded proteins originate from multiple pathways. Genetic mutations are 
often a tragic event that predispose a protein to unsuccessful folding. A defect in 
translational modification also contributes towards misfolding (Scheper, Van Der 
Knaap, & Proud, 2007). Failure of protein folding by chaperones is one of the other 
important factors that debilitates its function. In addition to compromising an 
individual proteins function, some of these misfolded proteins play a role in aberrant 
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RNA processing and formation of stress granules that subsequently direct towards 
aggregate formation. There are mechanisms in place that keep the protein properly 
folded, however, the mechanisms by which the protein is kept in homeostasis tends to 
devolve with time in a normal lifecycle of a cell. The ability of cells to control these 
mechanisms is a significant issue for research in aging (Ross & Poirier, 2004).  A 
dysfunction in any of the mechanisms that maintain proper protein folding leads to 
aggregation, making protein aggregation an important prognosis in disease pathology 
(Chiti & Dobson, 2006; De Baets et al., 2015). 
Protein aggregation occurs when a protein monomer or collection of proteins 
associates into a complex larger than its native state (Miyazaki et al., 2016). Misfolded 
proteins can become toxic to the cell when they aggregate because of exposed sequences 
that are usually buried within the hydrophobic core of the protein to the solvent solution 
surrounding it (Chiti & Dobson, 2006; De Baets et al., 2015). The hydrophobic cores of 
amyloidogenic proteins have aggregation prone regions (APRs) that, when exposed, have 
the potential to form intra- and intermolecular -strand interactions that are observed in 
aggregates(De Baets et al., 2015; Westerlund, von Heijne, & Emanuelsson, 2009). The 
consequences of protein aggregation as loss or gain of function is still debated. 
Nevertheless, this process which leads to cellular death is considered a symptom and in 
some cases a cause of disease (De Baets et al., 2015).  
There are many different characteristics to aggregates and aggregation pathways. 
For example, aggregation can be reversible as it is for yeast pyruvate kinase, Cdc19, 
where its low complexity domain (LCD) is dephosphorylated to reverse aggregation 
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(Höhfeld, 2017). On the other hand, aggregation can be irreversible as is seen with TDP-
43 where large SDS insoluble inclusions are formed (Lim, Wei, Lu, & Song, 2016). In 
addition, proteins have differing behaviors and localize to different cellular 
compartments. This may result in various, multistep aggregation pathways both between 
multiple proteins and within a single population of protein (E. Chi, Krishnan, & 
Kendrick, 2003; Van Buren, Rehder, Gadgil, Matsumura, & Jacob, 2009). Aggregation is 
a complex process that can be a product of protein instability (Treuheit, Kosky, & Brems, 
2002; W. Wang, 2005). The multiple mechanisms by which proteins aggregate can be 
more or less divided into three categories: 1) intermediate unfolded states, 2) self-
association or chemical linkages and 3) chemical degradation (W. Wang, Nema, & 
Teagarden, 2010).  
1.1.1 Intermediate Unfolded States 
Proteins in solution exist in an equilibrium of folded, intermediate, and 
unfolded/denatured states. Contrary to natively folded proteins which are less likely to 
aggregate because they do not have as many solvent exposed hydrophobic side chains, 
the intermediate states expose more hydrophobic patches. (W. Wang et al., 2010). 
Normal cell processes do one of three things with these intermediates: a protein will 
follow a traditional post- or co-translational pathway and fold to its native state, have a 
chaperone bind the intermediate and assist with proper folding to the native state, or the 
protein can be degraded by proteolysis mechanisms. In the absence of these processes 
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partially unfolded intermediate states of proteins may associate with other partially 
unfolded intermediate states and form aggregates (Fig.1A) (Fink, 1998).  
Figure 1.  Schematic illustrations of Mechanisms of Protein Aggregation A) the 
folding pathway of a native monomer exposes the hydrophobic core in the intermediate 
state which can serve as a catalyst for aggregation  B) Complementary patches on the 
surface of a native protein can lead to the formation of oligomers  C) Formation of a 
thermodynamically disfavored critical nucleus drives the formation of large irreversible 
aggregates D) Chemical degradation of the protein causes a conformational change that 
can drive the protein to aggregate 
 
Figure 2. TDP-43’s roles in RNA metabolism. TDP-43 plays pleiotropic effects in 
RNA metabolism pathwaysFigure 3.1 Schematic illustrations of Mechanisms of 
Protein Aggregation A) the folding pathway of a native monomer exposes the 
hydrophobic core in the intermediate state which can serve as a catalyst for aggregation  
B) Complementary patches on the surface of a native protein can lead to the formation of 
oligomers  C) Formation of a thermodynamically disfavored critical nucleus drives the 
formation of large irreversible aggregates D) Chemical degradation of the protein causes 
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1.1.2 Self-association 
Some protein monomers have the propensity to self-associate due to the self-
complementarity of their surfaces (Fig. 1B). This favors the formation of smaller 
reversible oligomers that encourage oligomer growth through processes such as 
nucleation and seeding, which is an aggregation process that produces large insoluble 
aggregates (E. Y. Chi, Krishnan, Randolph, & Carpenter, 2003). In this mechanism, a 
small oligomer is formed, termed the critical nucleus, that grows in size to form a large 
oligomeric species (Fig. 1C)(Philo & Arakawa, 2009).  
1.1.3 Chemical degradation  
Chemical degradation changes the physical properties of the protein bringing 
about a conformational change that may drive the protein towards aggregation. 
Conformational changes of the native fold to a nonnative state may spur aggregation by 
exposing the hydrophobic residues (Fig. 1D) (Chaturvedi, Siddiqi, Alam, & Khan, 2016; 
W. Wang et al., 2010). 
Aggregation is prompted by varying environmental stress conditions in vivo that 
can be mimicked experimentally in vitro (Kiese, Papppenberger, Friess, & Mahler, 2008). 
Stimuli of protein aggregation include: extreme temperature conditions, freeze-thaw 
cycles, mechanical stressors, and chemical modifications. Increasing temperatures disrupt 
intramolecular interactions in the protein and accelerate unfolding (Day, Bennion, Ham, 
& Daggett, 2002). At higher temperatures, proteins can be oxidized and deaminated 
leading to oligomerization (Brange, Havelund, & Hougaard, 1992). Oxidation of proteins 
is a major chemical degradation pathway that leads to aggregation (Shihong Li,’ 
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Christian Schoneich, 1995). In addition, freeze-thaw introduces interactions with ice 
crystals which can be a damaging stressor for proteins (Hillgren, Lindgren, & Aldén, 
2002; Kueltzo, Wang, Randolph, & Carpenter, 2008).  The native structure of the protein 
fold is not stable due to the protein-ice interactions that increase the solvent accessible 
surface area of the native fold (Strambini & Gonnelli, 2007).  
Aggregated proteins can be either soluble or insoluble in nature (Krielgaard et al., 
1998). Aggregation may occur following the chemical modification of the protein or its 
surroundings. Solubility can be dependent on buffer conditions which may stabilize the 
native state of the protein (Katayama et al., 2006) or lead to aggregation (Kameoka, 
Masuzaki, Ueda, & Imoto, 2007; Krishnan et al., 2002). Because major changes in pH 
can greatly affect protein stability, aggregation is correlated to changes in pH values 
(Kueltzo et al., 2008). Mechanical stressors disturb the processes that mediate the control 
mechanisms which target protein misfolding in a cell (Hachiya, Kozuka, & Kaneko, 
2008). Stirring and shaking are both mechanical stressors which induce aggregation in 
proteins  (Mahler, Müller, Frieß, Delille, & Matheus, 2005). Each of these driving factors 
make protein aggregation a complex process with important pathological implications in 
humans. 
1.2 TDP43 Biology and its implications in neurodegenerative disorders  
Gaining knowledge about the mechanisms by which neurological diseases work has 
become more accessible with the identification of specific proteins in the aggregates of 
affected cells. Here, we focus on the presence of trans-activation response (TAR) DNA-
binding protein 43 (TDP-43) (Fig. 4) and its role in neurodegenerative diseases. TDP-43 
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was first discovered to bind TAR element in human immunodeficiency virus 1 (HIV-1) 
(Ou et al., 1995).  TDP-43’s discovery in human disease occurred when it was found to 
induce exon skipping on a human cystic fibrosis transmembrane conductance regulator 
(CFTR) exon 9 by binding to the TG(m) repeat near the 3’ splice site (Morimoto & 
Cuervo, 2009). Since this discovery TDP-43 has been widely studied and has been shown 
to play major roles in RNA metabolism such as: pre-mRNA splicing, miRNA processing, 
lncRNA and ncRNA control, mRNA stability, mRNA transport, and mRNA translation  
(Ratti & Buratti, 2016)(Fig 2). TDP-43 has also been found in inclusions of postmortem 
brain tissue of patients with Amyotrophic lateral sclerosis (ALS) and  frontotemporal 
lobar degeneration (FTLD) making it a pathological marker for both of these disorders 
(Woollacott & Rohrer, 2016).  
Figure 2. TDP-43’s roles in RNA metabolism. TDP-43 plays pleiotropic effects in 
RNA metabolism pathways 
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1.2.1 ALS 
 ALS is a fatal motor neuron disease characterized by motor neuron degradation that 
leads to cell death in the central nervous system (CNS)(Bonafede & Mariotti, 2017; 
Brown & Al-Chalabi, 2017; Johnson et al., 2009; Morgan & Orrell, 2016). The effects of 
this disease are paralytic as the most common first symptom is loss of limb function with 
symptoms progressing to death resulting from respiratory failure (Brown & Al-Chalabi, 
2017). ALS is the most common motor neuron disease of the middle age community with 
symptoms appearing around the age of 50 (Cleveland & Rothstein, 2001). Recent data 
show that there are approximately 3 per 100,000 cases of ALS worldwide where 90% of 
cases are sporadic and 10% of cases are familial (Morgan & Orrell, 2016). First symptom 
to diagnosis is 12 months with a 3-5 year life expectancy after diagnosis (Kiernan et al., 
2011). Characteristics of mutant TDP-43 in ALS are loss of axonal transport function and 
RNA processing. These factors are suggested preface other factors of the disease 
pathology, however, the mechanism of pathology for ALS is unknown leaving no cure or 
preventative measures to take against this disease (Morgan & Orrell, 2016; Scotter, Chen, 
& Shaw, 2015).  
1.2.2 FTD 
Clinically, FTD presents with changes in cognitive abilities, personality, and behavior 
(Borroni et al., 2017; Haass & Neumann, 2016; Mackenzie & Neumann, 2016; 
Woollacott & Rohrer, 2016). It is part of a spectrum of neurodegenerative disorders being 
the second most common form of young onset dementia to be shown in patients under the 
age of 65 (Woollacott & Rohrer, 2016).  FTD’s pathology is diverse with the 
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accumulation of tau and TDP-43 in cells of the frontal and temporal lobes of the brain 
being a consistent features in the majority of cases (Haass & Neumann, 2016). FTD is 
often misdiagnosed due to overlapping symptoms that present as the disease progresses 
(Woollacott & Rohrer, 2016). Three mutations in MAPT, GRN, and C9orf72 have been 
identified to provoke the formation of the inclusions that lead to cell degeneration 
(Mackenzie & Neumann, 2016). Even with the knowledge of the mutations that cause 
proteins to form inclusions, there is no known cure for FTD as the mechanisms by which 
these inclusions form is still unknown and there is no assay that is able to pre-screen for 
the mutations (Borroni et al., 2017).   
1.2.3 CTE 
Chronic Traumatic Encephalopathy (CTE), described as “punch drunk” in the early 
1900s owing to its discovery and association with boxing  (Martland, 1928), is a 
neurodegenerative disorder with clinical symptoms similar to that of FTD and motor 
neuron disease: with symptoms including mental confusion, slower muscular movements, 
unsteadiness, and tremors (Stein, Alvarez, Mckee, & Traumatic, 2015). In the brain, CTE 
presents as neurofibrillary tangles and dot like inclusions (McKee & Gavett, 2010). CTE 
has been identified in athletes (Mckee et al., 2009), military veterans (Lee E. Goldstein, 
et al., 2012), victims of physical abuse (Stein et al., 2015), epileptics (Puvenna et al., 
2016), and in one case a dwarf who participated in dwarf throwing events in the circus 
(McKee & Gavett, 2010); all occupations where repetitive head trauma is routine.  CTE 
can be broken down into 4 stages with stage 1 being the mildest case and stage 4 the most 
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advanced. The extent of this disorder is still unknown and diagnoses is not thoroughly 
assessed until after death  (Stein et al., 2015). 
TDP-43 has been found hyperphosphorylated and ubiquitinated in the aggregates of 
affected neurons of ALS and FTD (Brown & Al-Chalabi, 2017; McKee & Gavett, 2010; 
Morgan & Orrell, 2016; Neumann, Sampathu, & Kwong, 2006). A known distinction of 
neurodegenerative diseases is the ubiquitination of misfolded proteins in the CNS; what 
distinguishes ALS and FTD from other similar neurodegenerative diseases is that the 
proteinaceous inclusion bodies are tau- and α-synuclein negative (Neumann et al., 2006). 
A known method of pathogenesis is the relocation of TDP-43 from the nucleus to the 
cytoplasm of neurons (Johnson et al., 2009) (Fig.3). A proposed mechanism for why this 
occurs is the overexpression of TDP-43. This occurs when there are mutations in its 3’ 
untranslated region (UTR) which may be a by-product of the decline of proteostasis 
(Bonafede & Mariotti, 2017). Aggregation puts stress on the cell proposedly by impairing 
RNA metabolism and isolating proteins important to routine cell function (Morgan & 
Orrell, 2016).  TDP-43, originally thought to only be associated with ALS and FTD, is 
Figure 3. TDP-43 forms cytoplasmic aggregates in neurodegenerative diseases. 
Aggregated TDP-43 is mis-localized from the nucleus to the cytoplasm in diseased 
neurons of patients with ALS, FTD, and CTE.    
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quickly being recognized to be associated with other neurological disorders as a 
subsidiary pathology such as is seen with CTE. TDP-43 mediates the response in axonal 
injury, such as axonal stretching due to traumatic brain injury, drawing further 
association between TDP-43 proteinopathies and head injury (Mckee et al., 2009).  
The discovery of the presence of TDP-43 positive inclusions in brain matter of 
patients with CTE has made repetitive brain injury a possible environmental stimulus for 
aggregation in TDP-43 proteinopathies. 
1.3 Structure of TDP43 
TDP-43 is a natively dimeric 414-residue protein that is encoded by the human 
TARDBP gene and present in inclusions of a wide variety of neurodegenerative disorders. 
The 43-kDa protein has three domains: a structured N-terminal domain, two RNA 
recognition motifs that bind RNA, and an unstructured C-terminal domain that mediates 
protein-protein interactions (Fig. 4A). All three domains are necessary for normal 
function of TDP-43 (Budini, Romano, Quadri, Buratti, & Baralle, 2015; Chiang et al., 
2016; Kuo, Doudeva, Wang, Shen, & Yuan, 2009; Zhang et al., 2013).  
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Figure 4 Structure of TDP-43. A) Combined structure of the TDP-43 protein. PDB files 
of each of the domains of TDP-43 were combined to create a proposed model for the full 
structure of TDP-43. Dotted lines represent the unknown residues that connect the 
structures. The positioning of the NTD relative to the RRMs was determined by data 
from small-angle X-ray scattering (Kuo et al., 2014). B) Secondary structure of the N-
terminal is captured from NMR structure of the PDB file 2N4P and consists of residues 
1-77. C) The flexible C-terminal tail is derived from NMR analysis PDB entry 2N3X. 
CTD spans residues 24-414 D) An illustrated domain analysis of the 414 amino acid 
protein with three domains: an N-Terminal, tandem RRMs, and a C-terminal. E) 
Secondary structure of RRM1, residues 106-175 bound to RNA derived from the PDB 
entry 4Y0F. F) Structure of RRM2 generated from the crystal structure of PDB entry 
3D2W; consists of residues 193-257.    
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1.3.1 N-Terminal Domain 
The highly conserved, 77 residue N-terminal domain (NTD) of TDP-43 plays an 
important role in TDP-43’s aggregation pathology and is suggested to play an important 
role in TDP-43’s physiology (Mompeán et al., 2016; Mompeán et al., 2017). The NTD 
has a unique structure with the monomer depicted as 2 sheets being comprised of 6 -
strands and 1 -helix. Sheet one is arranged with 2 strand antiparallel to 1, which in 
turn is parallel to 6, which is parallel to 3 (Fig. 5) having structural similarity to a 
ubiquitin like fold (Fig. 6). Sheet 2 is organized with 4 antiparallel to 5 (Fig. 5) having 
structural similarity to the C-terminal DIX domain of the protein axin-1 (Mompeán et al., 
2016). The NTD of TDP-43 readily oligomerizes at high concentrations and is composed 
as a dimer interface in wild type TDP-43(Chang et al., 2012). Hydrogen bonding and 
electrostatic interactions make up the intermolecular interface of the NTDs in  
Figure 5.  NTD of TDP-43. The NTD is composed of 6 β-strands and 1 α-helix. The β-
strands are separated into 2 β-sheets. Sheet 1, colored pink, consists of β1, β2, β3, and β6. 
Sheet 2, green, contains β4 and β5. The α-helix is colored purple. 
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TDP-43.The intermolecular interface of the TDP-43 NTD dimer is made up of an 
asymmetric unit arranged in a “head-to-tail” morphology mediated by hydrogen bonding 
and electrostatic interactions. The positively charged head interacts with the negatively to 
Glu17 on 2 (tail); Arg55 on 4 (head) to Glu21 on 1-1 loop (tail); and Asn76 on 5 
(head) to Gln34 on 1 (tail). The Glu17 on the 2 strand of one monomer hydrogen 
bonds in a parallel manner to Met51 and Gly53 on the backbone of the 4 strand on the 
second monomer to create an intermolecular -bridge. This interface is strengthened by 
the salt bridge created when the carboxyl of Glu17 hydrogen bonds with the hydroxyl of 
Ser48 and the carboxamide group of Asn45 in a site specific manner (Fig. 7) 
 
 
Figure 6 NTD of TDP-43 adopts a ubiquitin-like fold. Overlay of structures TDP-43 
(teal) PDB: 2N4P and Ubiquitin (coral) PDB: 1TBE show that sheet 1 of TDP-43 shares 
structural similarities with the ubiquitin fold. Sheet 2 of TDP-43 does not share 
similarities with Ubiquitin. 
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Figure 7. Domain interaction of TDP-43 NTD Dimer. Representation of two NTD 
monomers, NTD1 (Teal) and NTD2 (Green), in a dimer formation. Crystal structure of 
the NTD dimer (PDB:5MDI) reveal hydrogen bonds (Red dotted lines) making inter-
molecular contacts at specific residues depicted as stick figures on the structure.  
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 (Afroz et al., 2017). This thesis gives evidence of how a phosphomimetic mutation at 
Ser48 delays oligomerization of full length TDP-43 by disturbing NTD dimer 
interactions which has been previously described to interrupt self-association (A. Wang et 
al., 2018). Residues 77-108 of the NTD belongs to the nuclear localization signal (NLS) 
of TDP-43. This region serves as a tag for transport into the nucleus (Lange et al., 2007). 
In addition, this region is highly disordered and due to its cationic nature has the ability to 
bind nucleic acids  (Mompeán et al., 2016). Unlike the CTD of TDP-43, the NTD fold is 
highly structured and very stable (Chang et al., 2012). Studies show that the NTD is 
necessary for physiological function and for TDP-43 aggregation; however, the method 
by which this domain directly contributes to the pathologic mechanism of TDP-43 
aggregation is still being investigated (Mompean et al., 2016).   
1.3.2 RNA Recognition Motifs  
One of the most abundant eukaryotic protein domains is the RNA recognitions 
motif (RRM) (Cléry, Blatter, & Allain, 2008). The main functions of this protein domain  
are to mediate RNA binding and protein-protein interactions (Maris, Dominguez, & 
Allain, 2005). Typical RRM structures contain folds of a -sheet packed against2 -
helices. There are two highly conserved domains of 8 and 6 amino acid residues called 
ribonucleoprotein domain (RNP) 1 and RNP 2 respectively, that associate with single 
stranded nucleic acid through π stacking interactions to the flat side of a -sheet. Each 
RRM has the ability to bind a minimum of 2 and a maximum of 8 nucleotides (Kuo, 
Chiang, Wang, Doudeva, & Yuan, 2014; Landsman, 1992). 
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TDP-43 forms a homodimer with 4 RRMs  with each monomer containing 2 RRMs 
deemed RRM1, residues 106-175, and RRM2, residues 193-257 (Emanuele Buratti & 
Baralle, 2001). Crystal structures of RRM1 (PDB:4Y0F) (Chiang et al., 2016) and RRM2 
(PDB:3D2W) (Kuo et al., 2009) reveal structures similar to that of typical RRMs with a 5 
stranded -sheet packed against 2 -helices (Fig. 8) (A. Wang et al., 2018). Both RRMs 
have topologies of 2-3-1-5-4 with the conserved RNP1 and RNP2 located in 1 
and 3 respectively. RRM1 has a longer loop between 1 and 3 making it slightly larger 
than RRM2 (Kuo et al., 2014).  
TDP-43 has a specificity for poly-UG/TG repeats and will bind a minimum of 6 
TG/UG repeats with RRM1 dominating the binding process by binding the majority of 
Figure 8. Individual RRMs.  Ribbon structures generated from the crystal structures of 
the individual RRMs with RNA, RRM1 (Blue, PDB: 4Y0F) and RRM2 (Orange, PDB: 
3D2W), have topologies similar to that of typical RRM domains 
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the nucleotides and RRM2 acting in more of a supporting role for nucleic acid binding 
(Furukawa et al., 2016).  Phenylalanine (Phe) plays an important role in nucleic acid 
binding which is made apparent when mutations that change 5 Phe to Leucine (Leu) in 
the RRMs inhibit nucleic acid binding  (Gopal, Nirschl, Klinman, & Holzbaur, 2017) 
Figure 9. TDP-43 RRMs bind UG nucleotides. Secondary structure of TDP-43 
tandem RRMs (RRM1: Blue; RRM2: Orange) with and AUG12 RNA (5′- 
GUGUGAAUGAAU-3′) bound (Dark Grey) (PDB: 4BS2) reveal π stacking 
interactions with Phenylalanine residues. A) Phe231 π-stacks with G. B) Phe147 π-
stacks with U. C) Phe194 π-stacks with U. D) Phe149 π-stacks with G. 
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1.3.3 C-Terminal Domain  
The C-terminal Domain (CTD) of TDP-43 is the most studied of the domains due 
it containing the majority of disease related mutations in ALS (Conicella et al., 2017). 
Nuclear magnetic resonance spectroscopy (NMR) and molecular dynamic (MD) 
simulations have been used to determine the conformation of this domain because of its 
intrinsically disordered nature (Mompeán et al., 2015). The CTD has a low-complexity 
sequence, which is not uncommon for eukaryotic RNA binding proteins 
 (Conicella et al., 2017).  Only one section of the CTD, residues 319-341, have sequence 
conservation with vertebrates resulting in a fragmented conservation of this domain, 
however, the CTD has  
a 24% sequence identity with the N-terminus of the Sup35 yeast prion domain resulting 
in the CTD being “prion-like” (Lim et al., 2016).  
Secondary structure predictions by NMR and MD simulations determine the 
CTD, spanning residues 274-414, to adopt a helix-turn-helix conformation with three 
defined domains: a glycine rich domain (GRR) which functions to recruit cellular factors 
that modulate cytoplasmic inclusion of TDP-43 (D’Ambrogio et al., 2009), an Asn/Gln 
rich motif which is capable of aggregation and has been seen to recruit normal TDP-43  
Figure 10. C-Terminal Domain. The C-terminal domain of TDP-43 is highly 
disordered. Secondary structure analysis by NMR (PDB: 2N3X) reveals a 
prominent α-helical domain. 
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into aggregates (Mompeán et al., 2014), and a hydrophobic patch which has been 
proposed as an initiator for aggregation in mechanistic studies (Jiang et al., 2013). An α-
helical segment from 321-330 and a β-hairpin structure with a turn separating two  
Asn/Gln regions from residues 341-357 are two sections that have been defined by NMR 
and MD simulations. It has also been determined that residues 358-367 form a defined β-
turn, which is followed by a random coil which makes up the flexible tail (Mompeán et 
al., 2015)(Fig. 10). 
The CTD of TDP-43 is highly aggregation prone and there have been many 
experiments done on this domain to determine its function in TDP-43 pathology. 
Mechanism prediction experiments show that the residues from 311-360, which normally 
Figure 11. Illustration of proposed CTD aggregation by β-strand expansion 
modeled by MD Simulations.  The glycine-rich region of the CTD has been 
described by molecular dynamic simulations to form anti-parallel β-hairpins. 2 β-
strands form a single β-sheet. Aggregates are formed by interactions between β-
sheets.    
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adopted an α-helix structure in the CTD goes through a structural transformation that 
triggers unfolding to a β-sheet rich structure, which spontaneously associates and can 
serve as a “nucleus” for aggregation (Jiang et al., 2013). MD simulations show an 
amyloid like β-topology where the β-hairpins laterally associates in parallel contributing 
2 β-strands to one β-sheet (Mompeán et al., 2015)(Fig.11). It is proposed that 
oligomerization occurs through this β-strand expansion (Mompeán et al., 2014).  
As mentioned earlier, the majority of disease mutations in ALS are found in the 
CTD of TDP-43. The specific mutation Q331K, where the 331 glutamate is mutated to a 
lysine is found in the middle of the α-helical structure. This mutation disrupts the -helix 
structure and is toxic to the cell (Arnold et al., 2013; Conicella et al., 2017).  
1.3.4 Domain Contributions to Aggregation 
 TDP-43 is known to have aggregation prone properties, however, the molecular 
mechanisms by which TDP-43 aggregates form is still largely unknown (Yang et al., 
2010). Studies have identified regions of the different domains of TDP-43 to have 
individual factors that can contribute to aggregation of the full length protein. The NTD 
of TDP-43 has been shown to oligomerize in a concentration dependent manner with 
circular dichroism data (CD) suggesting that the oligomerization is mediated by the β- 
sheets on the surface of the NTD (Chang et al., 2012). A short 10 residue region on 
RRM2 has been shown to have polymorphic capabilities that are apparent in pathological 
amyloid aggregation (Guenther et al., 2018). In addition to the MD simulations that 
hypothesize β-strand expansion as an inducer for aggregation, the CTD of TDP-43 has 
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glycine and Q/N-rich regions which have been shown to form fibrilar amyloid-like 
aggregates in vivo (Prasad, Sivalingam, Bharathi, Girdhar, & Patel, 2018).  
1.4 Nucleic Acid Binding 
TDP-43 is a nucleic acid binding protein known to bind specifically to poly-UG 
repeats by its RRMs in the 3’ to 5’ direction.  (E Buratti et al., 2001; Sun & Chakrabartty, 
2017).  As stated previously, RRM1 has more involvement in the nucleic acid binding 
process while RRM2 is more of a support system. This is confirmed in pull down  
experiments where, when independent of each other, RRM2 did not bind nucleic acid 
while RRM1 had high affinity for single stranded nucleic acid. When in a complex, the  
RRMs bound UG/TG repeats with high affinity suggesting that RRM2 plays an important 
role in sequence specificity (Furukawa et al., 2016).   
A nucleic acid binding model suggests that in the presence of RNA the RRM1 
will bind and dissociate from the UG nucleotides with Kd values of ~110 nM (Bhardwaj, 
Myers, Buratti, & Baralle, 2013). This supports the need for longer oligonucleotide repeat 
sequences so that the TDP-43 RRM can continuously bind the subsequent U and G in the 
sequence. A crystal structure of RRM1 has revealed the specific interactions of nucleic 
acid with TDP-43 where a T-G dinucleotide is recognized by Loop 1 and a G-T-G 
sequence interacts with a β-sheet (Kuo et al., 2014). Two aromatic residues in RRM1, 
Phe147 and Phe149, are known to make π stacking interactions with uracil (U) and 
guanidine (G) on RNA (Ayala et al., 2005). As  mentioned previously, when these 
aromatic residues are mutated to aliphatic leucine they are no longer able to participate in 
stacking interactions with RNA, and binding is diminished (Cohen et al., 2015) (Fig.12).  
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Figure 12. PheLeu mutation in RRM1 disrupts RNA binding. Phe147 and Phe149 
form π-tacking interactions with U and G in RNA (Kuo et al., 2014). When 
Phenylalanine is mutated to a Leucine binding of RNA can no longer occur. 
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1.4.1 Uncertainty in RNA Binding Models  
 TDP-43 is known to bind UG/TG repeats of RNA/DNA through its RRMs 
however, other probable processes for RNA binding with TDP-43 have been discussed. 
Anisotropy measurements monitoring binding affinity of the NTD in complex with the 
RRMs had a 3-fold higher binding affinity than the RRMs alone suggesting that the NTD 
contributes to nucleic acid binding in the full length TDP-43 (Chang et al., 2012). The 
NLS of TDP-43 is also cationic and has the ability to bind TT and TG repeat DNA 
(Mompean et al., 2016). Another study has shown that direct binding of RNA to the 
glycine rich region in the CTD of TDP-43 was able to prevent aggregation of cleaved C- 
terminal fragments of TDP-43 (Kitamura, Shibasaki, Takeda, Suno, & Kinjo, 2018). A 
better understanding of the binding models of RNA/DNA to TDP-43 could aid in 
identifying possible interventions to the neurodegenerative diseases in which aggregated 
TDP-43 is present.  
1.5 Ribonucleoprotein Complexes 
Ribonucleoprotein (RNP) Complexes form when RNA and RNA-binding proteins 
associate. These RNA-protein complexes have been shown to increase the solubility of 
aggregation prone proteins by improving protein-folding pathways  (Choi et al., 2008). 
TDP-43 is a RNP known to have a high specificity for poly TG/UG repeats. While TDP-
43 is known to aggregate in a variety of environmental stressors, nucleic acid binding has 
been shown to suppress aggregation of TDP-43 in in vitro heat stress conditions (Huang 
et al., 2013). In an experiment testing the propensity of nucleic acid to inhibit 
aggregation, the presence of TG12 repeats showed substantially less aggregated species 
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than AC12 repeat and a no RNA control species (Sun, Arslan, Won, Yip, & Chakrabartty, 
2014).  
Aggregated TDP-43 has been found in inclusions located in the brain matter of 
patients with CTE. It has been speculated that the violent shaking of neuronal cells may 
serve as an inducer for TDP-43 aggregation in these inclusions (McKee & Gavett, 2010). 
Given that TG12 repeats attenuate TDP-43 aggregation in heat stress conditions we 
speculate that the addition of TG12 repeats to agitated TDP-43 may attenuate aggregation 
as well. In this study, with turbidity measurements using agitation induced aggregation, 
fluorescence assays, and sedimentation analysis, we observe the aggregation potential of 
dimeric TDP-43 and investigate the propensity of DNA/RNA sequences to inhibit TDP-
43 aggregation when shaken vigorously.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 LIC Cloning 
Human wild type (WT) TDP43, Q331K, and 5FL ORFs were cloned into the 
pET His6 GFP TEV LIC cloning vector (1GFP) (Addgene) or pET Biotin His6 mCitrine 
LIC cloning vector (mCitrine) using a ligation independent cloning protocol (LIC) (QB 
Berkley) by a previous graduate student. LIC cloning is based on making DNA strands 
single stranded and complimentary to each other. Primers for 1GFP and mCitrine cloning 
were designed as described by QB3 MacroLab LIC Expression Vectors cloning manual 
to anneal to the desired digestion site at 55°C and to include a C terminal stop codon in 
the amplified ORF. The digestion site was created by linearizing the 1GFP and mCitrine 
vectors with the enzyme SspI at 37°C for 1 hour. Primers were created by designing a 3’ 
end complementary to the insert target 20-25 bp long with a Tm of ~60 °C ending with a 
3’ G or C (Table S1). The TDP43 (Addgene; #27458), Q331K (Addgene; #27461) or 
5FL(Addgene;#29608) GFP or mCitrine plasmid construct was transformed into 
Rosetta or BL21 competent cells, plated on LB plates containing 50ug/mL Kanamycin 
(GoldBio) and 25ug/mL Chloramphenicol (GoldBio) for Rosetta’s or 50ug/mL 
Kanamycin (GoldBio) for BL21’s, and incubated at 37C overnight.
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2.2 Site Directed Mutagenesis 
Q5® Site Directed Mutagenesis Kit (New England Biolabs, Ipswich, MA, USA) 
was used to substitute GAG (glutamate) for TCT (serine) in the pET His6 GFP-TEV-
TDP-43. Primers were designed using NEBase changer from New England Biolabs 
(Ipswich, MA,www.neb.com). The substitution from serine to glutamate was 
incorporated in the center of the forward primer with nucleotides of complementarity 
downstream from the mutation point GAATCCAGTGGAGCAGTGTATGAGAGGTG -
3’. The reverse primer was designed with the 5’ ends of the two primers annealing back 
to back: 5’- CTGTAGCGAAGCCCACAC -3’. Thus the entire pET His6 GFP-TEV-
TDP-43 plasmid was PCR amplified and transferred to a Kinase, Ligase, Dpn1 (KLD) 
reaction. The newly sythesized GFP-TEV-S48E plasmid construct was then transformed 
into BL21 competent cells, plated on LB plates containing 50ug/mL Kanamycin, and 
incubated at 37C overnight. Mutations were verified by DNA sequencing (Quintara 
Bio). Expression and purification was performed using the methods described below.  
2.3 Expression and Purification 
Starter cultures were prepared by inoculating single bacterial colonies into 50mL 
of LB medium containing appropriate antibiotic and incubated at 37C overnight. The 
overnight culture was used to inoculate 1L of LB medium containing the appropriate 
antibiotic. The cells were then grown to an OD600  0.4, cooled to 19C and induced by a 
final concentration of 1 mM IPTG (isopropyl-β-thiogalactopyranoside) and then 
incubated for 6 hours. The cell culture was centrifuged at 8000 RCF for 30 minutes. The 
pellet was suspended in a minimum amount of Lysis Buffer (40mM HEPES, 300mM 
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NaCl, 1mM MgCl2, 50mM Imidazole, 5mM Me, 10% Glycerol, and complete EDTA 
free protease inhibitor, pH 7.5). CHAPS (1%), DNAse (20g/L), and Lysozyme 
(0.25mg/mL) were added to the suspension and incubated with stirring at 4C for 1 hour. 
The suspension was centrifuged at 31000 RCF for 75 minutes and the lysate was filtered 
through a 0.22M bottle top filter (Genesee). Lysate was then loaded using a sample 
pump onto an 8mL nickel immobilized metal affinity chromatography (IMAC) column 
(Biorad) in an NGC System (BioRad) at 4°C. The column was washed with 5 column 
volumes (CV) of Lysis Wash Buffer followed by a modified Elution Buffer (40mM 
HEPES, 300mM NaCl, 1mM MgCl2, 500mM Imidazole, 5mM Me, and 10% Glycerol, 
pH 7.5). The proteinaceous fractions were collected and immediately loaded onto a pre-
equilibrated Superdex 200 16/600 Size exclusion Column (GE Life Sciences) to get a 
homogenous protein sample. Protein was eluted using an SEC Buffer (40mM HEPES, 
300mM NaCl, and 5mM DTT, pH 7.5). Purified fractions were collected and 
immediately used for analysis.  
2.4 Denaturing Expression and Purification 
Starter cultures were made by inoculating single colonies into 50mL of LB 
medium containing appropriate antibiotic and incubated at 37C overnight. The overnight 
culture was used to inoculate 1L of LB medium spiked with appropriate antibiotic. The 
cells were then grown to an OD600  0.4, cooled to 19C, induced by a final concentration 
of 1 mM IPTG (isopropyl-β-thiogalactopyranoside), and then incubated for 6 hours. The 
cell culture was centrifuged at 8000 RCF for 30 minutes. The pellet was suspended in a 
minimum amount of Lysis Buffer (40mM HEPES, 300mM NaCl, 1mM MgCl2, 50mM 
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Imidazole, 5mM Me, 10% Glycerol, and complete EDTA free protease inhibitor, pH 
7.5). CHAPS (1%), DNAse (20g/L), and Lysozyme (0.25mg/mL) were added to the 
suspension and incubated with stirring at 4C for 1 hour. The suspension was centrifuged 
at 31000 RCF for 75 minutes and the lysate was filtered through a 0.22M bottle top 
filter (Genesee). Lysate was then loaded onto an 8mL nickel Immobilized metal affinity 
chromatography (IMAC) column (Biorad) in an NGC System (BioRad). The column was 
washed with 5 column volumes (CV) of Lysis Wash Buffer, then washed with a 
Denaturing Wash Buffer (40mM HEPES, 300mM NaCl, 1mM MgCl2, 500mM 
Imidazole, 5mM Me, 10% Glycerol, and 6M Urea; pH 7.5) followed by a modified 
Elution Buffer (40mM HEPES, 300mM NaCl, 1mM MgCl2, 500mM Imidazole, 5mM 
Me, 10% Glycerol, and 6M Urea; pH 7.5). The proteinaceous fractions were collected 
and immediately loaded onto a Superdex 200 16/600 Size exclusion Column (GE Life 
Sciences).Protein was eluted using an SEC Buffer (40mM HEPES, 300mM NaCl, 6M 
Urea, and 5mM DTT; pH 7.5). Purified fractions were collected and immediately used 
for analysis.  
2.5 In vitro Aggregation Studies  
Purified protein typically eluted off the size exclusion column at ~7µM and was 
further diluted to a final concentration of ~3µM in a buffer containing 25mM HEPES, 
170mM NaCl, and 3mM DTT at pH 7.5. Diluted protein was incubated at 25C with 
agitation at 1400 RPM in an Eppendorf Thermomixer for 4 hours in the presence or 
absence of oligonucleotides. Turbidity measurements taken using a Tecan Infinite® 
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M1000 plate reader at an absorbance of 395nm were used to assess aggregation. 
Measurements were taken at 25°C.  
2.6 Fluorescence Assays 
Purified protein samples (5M) in SEC buffer (40mM HEPES, 300 mM NaCl, 
and 5mM DTT; pH 7.5) were subjected to fluorescence intensity scans with GFP 
excitation at 488nm in the presence or absence of oligonucleotide (IDT).Emission spectra 
were measured from 500-700nm using a Tecan Infinite® M1000 plate reader. Protein 
was then subjected to agitation as described above. After agitation samples were spun 
down at max speed (21120 RCF) to pellet aggregated protein. Fluorescence spectra were 
measured on the supernatant as described above. 
2.7 Sedimentation Analysis of Aggregation Experiments 
We performed a sedimentation analysis as was described in a previous study 
(Johnson et al., 2009). After in vitro agitation experiments the insoluble fraction (pellet) 
was separated soluble fraction (Supernatant) by centrifugation at 21130 x g for 60 min at 
25°C. A denaturing SDS PAGE gel was used to analyze protein species in the 
supernatant and pellet. To accomplish this supernatant was decanted and pellet 
resuspended in equal volume ( ~50µL) of Laemmli Loading Buffer (BioRad). 15µL of 
both supernatant and pellet fractions were loaded onto an SDS PAGE gel and analyzed 
for comparison.  
2.8 Dynamic Light Scattering 
Dynamic light scattering (DLS) measurements of the hydrodynamic radius (Rh) 
were taken at 25°C with a DynaPro® Plate Reader II (Wyatt Technologies) using a 96 
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well half area plate (Corning). Proteinaceous fractions (~7µM) in an in SEC buffer 
(40mM HEPES, 300 mM NaCl, and 5mM DTT; pH 7.5) were filtered through 0.22µM 
PES filters prior to analysis to remove large species. Regularization analysis was 
determined using DYNAMICS (Wyatt) software with 5 consecutive measurements taken 
over a 5 second time frame. Autocorrelation decay curves were used to calculate the 
particle translation diffusion coefficient. The Stokes-Einstein equation (𝐷𝑡 =  
𝑘𝑇
6𝜋𝜂𝑅ℎ
 ;Dt is 
the diffusion coefficient, k is the Boltzmann constant, T is absolute temperature in 
Kelvin, η is the viscosity of the solvent, and Rh is the hydrodynamic radius.) was then 
applied to determine the Rh of the particles in solution and the DYNAMICS software was 
used to create histograms of % mass vs. Rh for analysis.  
2.9 Determining Concentration of TDP-43 
A Pierce™ BCA Protein Assay kit was used for the total protein quantification. 
Following the protocol described in the Pierce™ BCA Protein Assay manual, 2mg/mL 
Bovine Serum Albumin (BSA) protein standards (Thermo Scientific) were serially 
diluted to a working range which were then used to create a standard curve to determine 
protein concentration of WT TDP-43 and mutants. To 25µL of BSA standard of a known 
concentration, 175 µL of working reagent (WR) was added to create a final concentration 
of 1:8 (v/v) protein to working reagent in a 96 well plate (Corning). The same was carried 
out for the unknown concentration of TDP-43 or mutant. The solution was thoroughly 
mixed for 30 seconds and immediately incubated at 37°C for 30 minutes. After 
incubation the solution was cooled to room temperature (RT) and the absorbance was 
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measured at 562nm. The resulting BSA standard curve was used to extrapolate protein 
concentrations of the samples.  
2.10 AUG12 RNA 
The 12-mer RNA in this study was transcribed using a recently published protocol 
(Chapman, Moon, Wilusz, & Kieft, 2014). Oligomers purchased from IDT containing a 
T7 promoter site were annealed together by heating to 95°C and snap cooled to 4°C for 
transcription by T7 RNA Polymerase (Table S2). Following transcription RNA was 
purified using a PLRP-S Chromatography Column on an Infinity II HPLC system 
(Agilent). Purity of RNA was analyzed using 10% dPAGE and concentration was 
determined on a Nanodrop OneC (Thermo Scientific).Due to the small size of the RNA 
buffer exchange and desalting was accomplished by ethanol precipitation where 1 
volume of RNA solution was added to 3 volumes of 100% ethanol and 1/10 volume of 
sodium acetate (NaOAc) and precipitated at -80°C  overnight. The precipitated solution 
was then spun at >21,000 x g for 1 hour at 4°C. The supernatant was decanted and  the 
pellet was suspended in minimal amount of HyPure™ Molecular Biology Grade water 
(GE Life Sciences) flash frozen in liquid nitrogen aliquoted and stored at -80°C.  
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CHAPTER 3: RESULTS 
3.1 WT TDP-43 Readily Forms Aggregates  
We set out to obtain purified monomeric TDP-43 protein in order to complete in 
vitro aggregation experiments. TDP-43 protein has been reported to be inherently 
aggregation prone in previous in vitro studies (Johnson et al., 2009; Sun et al., 2014). The 
TDP-43 open reading frame (ORF) gene was cloned into an expression vector containing 
an N-Terminal monomeric enhanced green fluorescent protein (mEGFP) tag to act as a 
fluorescent probe. mEGFP is a derivative of green fluorescent protein which fluoresces 
more intensely and is less susceptible to unfolding (Gambotto et al., 2000).  This 
construct was expressed in Escherichia coli using buffers adapted from previous studies 
(Sun et al., 2014).  
The quality of protein purification was assessed using Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) gels, size exclusion chromatography 
(SEC) and dynamic light scattering (DLS) measurements. SDS-PAGE of the eluted 
sample shows the presence of a band at 75kDa which agrees with the size of the 
recombinant GFP-TDP-43 monomer (Fig. 13C). However, size exclusion 
chromatography shows the WT protein eluting in the void volume of the column 
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Figure 13. Characterization of WT GFP-TDP-43. A) Purification and analysis by 
SEC. Overlay of GFP-TDP-43 purified under standard conditions with Size Standards 
(BioRad). The single elution peak before 0.4CV reveals an aggregated species B) Size 
determination by DLS using ~7uM protein confirms large species. Rh is calculated by 
%mass using DYNAMICS software (Wyatt). C) SDS-PAGE of purified GFP-TDP-43. 
Lanes contain eluted fractions from Nickel affinity purification (Nickel) and SEC 
purification (Eluent 1) compared against Precision Plus Protein Ladder (Bio-Rad). 
Samples were run on a 4-20% polyacrylamide gel for analysis.    
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suggesting an aggregated species larger than 670kDa. This was assessed by overlaying 
elution peaks of GFP-TDP-43 with BioRad size standards (Fig. 13A).  
DLS was used to assess the particle size of the species in solution by measuring 
the translational diffusion coefficient (Dt) from which a hydrodynamic radius can be 
calculated using the Stokes-Einstein relation (See materials and methods). The Dt is 
calculated from an autocorrelation function which plots the average overall intensity of 
scattered light within a given time interval.  DLS measurements give two species. One 
species has a radius of 13.3 nm which constituted 12% of the sample by mass and the 
second species is 109.3nm constituting 88% of the species by mass (Fig. 13B). Regarding 
absolute stoichiometry’s, DLS measures the diffusion of particles in solution and does 
not deliver a proper molar mass. Molar mass is estimated by the DYNAMICS software 
using models that assume relationships between Rh and mass (𝑀(𝑟) ∝ 𝑟3) where the 
DYNAMICS software assumes a spherical shape for the Rh. Conversion of radius to mass 
for the first species gives an estimated mass of 1428 kDa and the second species 198338 
kDa. These results are inconsistent with previous studies that were able to purify the 
dimer from nickel affinity purification methods (Sun et al., 2014).  
TDP-43 was also cloned into a vector containing a C-terminal mCitirine (mCit) 
fluorescent tag. mCit is a variant of YFP that has been modified to be more highly 
expressed (Griesbeck, Baird, Campbell, Zacharias, & Tsien, 2001).  Purification of the 
TDP-43-mCit vector was almost identical to that of the GFP-TDP-43 variant. SDS-PAGE 
confirms the presence of the protein and DLS measurements and SEC analysis both 
confirm the presence of a multimer.  
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Our results suggest that purification of the WT GFP-TDP-43 plasmid with the N-
terminal EGFP and the TDP-43-mCit plasmid with a C-terminal mCitrine in adapted 
buffers does not yield a dimeric TDP-43 protein.  
3.2 Urea Denaturing Purification yields an aggregated TDP-43  
Difficulties in purifying full length monomeric TDP-43 have been previously 
reported (A. Wang et al., 2018). To improve purification, aggregated proteins have been 
unfolded in urea then subsequently refolded in a buffer, absent of urea back to their active 
form (Yamaguchi & Miyazaki, 2014).  Denaturing purification of WT TDP-43 using 6M 
urea in wash and elution steps was used after native/ non-denaturing purification failed to 
produce a monomeric protein species for further analysis. The GFP-TDP-43 construct 
was expressed in Escherichia coli using lysis wash and elution buffers, outlined in the 
methods section, supplemented with 6M urea during purification. Initial purification 
methods where modified lysis wash buffer with 6M urea was used to suspend cell pellet 
and equilibrate the Ni/NTA column resulted in no protein binding to the column (Fig. 
S1).  
Alternatively, resuspension of the cell pellet and equilibration of the Ni/NTA 
column was performed in lysis wash buffer without urea with subsequent purification 
steps completed with the modified lysis wash buffer with 6M urea. A single species at 
~75kDa was identified by SDS-PAGE confirming the TDP-43 was present in the eluent 
(Fig 14C). SEC purification generated a single species that eluted in the void volume (Fig 
14A). DLS measurements showed a multimeric species that constituted 95% of the  
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Figure 14.Characterization of GFP-TDP-43 in a native purification followed by 
Urea. A) Size exclusion chromatogram of TDP-43 WT Urea (orange) and size standards 
(blue). The short retention time of “eluent1” in TDP-43 WT Urea is consistent with a 
large aggregate. Retention time of “eluent 2” is smaller than the oligomer in “eluent 1” 
but still a larger oligomer than desired. B) Size determination by DLS using ~7uM of 
“eluent 2” confirms large species. Rh is calculated by mass with DYNAMICS software 
(Wyatt). C) SDS-PAGE of purified GFP-TDP-43. Lanes contain eluted fractions from 
Nickel affinity purification (Nickel 1-3) and SEC purification (Eluent 1-2) compared 
against Precision Plus Protein Ladder (Bio-Rad). Samples were run on a 4-20% 
polyacrylamide gel for analysis.    
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sample by mass with a radius of 11.5 nm (Fig 14B). This verifies the species that eluted 
was aggregated WT GFP-TDP-43. Our data present WT GFP-TDP-43 as a urea soluble 
multimer. 
3.3 A S48E Phosphomimic Mutant Maintains Dimer Conformation after Purification   
Recent studies have identified a residue in the NTD involved in post-translational 
modification which, when phosphorylated, disrupted NTD self –assembly (A. Wang et 
al., 2018). Previous reports confirm that the NTD mediates TDP-43 oligomerization 
(Afroz et al., 2017).  We corroborate the results that the phosphomimetic mutation, S48E, 
would favor in producing a species viable for aggregation studies.  
Using site directed mutagenesis, we created a mutated TDP-43 construct with a 
glutamate substituted for serine at the 48th residue in the NTD, S48E. The new construct,  
GFP-S48E-TDP-43, was expressed and purified under standard nondenaturing 
conditions. SEC purification resulted in two species, an aggregated species eluting in the 
void volume and another species eluted at 0.6 CV (eluent #2) (Fig 15A). This second 
species was of extreme interest as it eluted with a peak consistent with the retention time 
of -globulin (bovine) in the BioRad Gel Filtration Size Standards, which has a molecular 
weight of 158kDa which is consistent with the dimer of TDP-43 (Fig 13A). 
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Figure 15. Characterization of GFP-S48E-TDP-43. A) Size exclusion chromatogram 
of S48E (orange) and size standards (blue). The short retention time of “eluent1” in S48E 
is consistent with a large aggregate. “Eluent 2” had a symmetric peak at a longer 
retention time consistent with a species closer to that of a dimer.  B) Size determination 
by DLS using ~7uM of “eluent 2” sample. Rh is calculated by mass with DYNAMICS 
software (Wyatt). C) SDS-PAGE of purified GFP-TDP-43. Lanes contain eluted 
fractions from Nickel affinity purification (Nickel) and SEC purification (Eluent 1-2) 
compared against Precision plus Protein Ladder (Bio-Rad). Samples were run on a 4-
20% polyacrylamide gel for analysis.  Green arrow depicts purified dimer species. 
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Analysis by DLS identified the second species with 96% of the sample by mass to have a 
radius of 5.2 nm (Fig 15B). Conversion of radius to molecular weight gives an 
approximate mass of 160 kDa. SDS-PAGE revealed a single species at 73kDa confirming 
“elution #2” to be the GFP-S48E-TDP-43 protein (Fig 15C). Purification of the GFP-
S48E-TDP-43 phosphomimetic mutant resulted in a purified dimer protein. We observe 
that the phosphomimetic mutant was able to delay formation of aggregated TDP-43 
protein. 
Denaturing purification of the GFP-S48E-TDP43 mutant was completed in an 
attempt to attain a monomeric protein species. The mutant construct was expressed and 
purified in the same fashion as the wild type. SDS-PAGE confirmed the presence of the 
mutant construct in the elution with a single band at ~75kDa. SEC elution profile and 
DLS both confirm the presence of an aggregated species (Fig. 16A and B). The SEC 
elution profile shows a shifted second peak to a longer retention time indicating a smaller 
but still oligomeric species. DLS analysis reveals a mutlimeric species with a species 
populating 33% of the sample by mass and another populating 53% of the species by 
mass. These species displayed radii of 17.2nm and 118.0nm respectively estimating 
masses of 2665 kDa and 236841 kDa. These results are consistent with the wild type 
denaturing purification suggesting that urea denaturation yields an oligomeric species. 
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Figure 16. Characterization of GFP-S48E-TDP-43 in denaturing conditions. A) 
Size exclusion chromatogram of S48E Urea (orange) and size standards (blue). The 
short retention time of “eluent1” in S48E is consistent with a large aggregate. Retention 
time of “eluent 2” is smaller than the oligomer in “eluent 1” but still a larger oligomer 
than desired. B) Size determination by DLS using ~7uM of “Eluent 2” protein. Rh is 
calculated by mass with DYNAMICS software (Wyatt). C) SDS-PAGE of purified 
GFP-S48E Urea. Lanes contain eluted fractions from Nickel affinity purification 
(Nickel) and SEC purification (Eluent 1-2) compared against Precision plus Protein 
Ladder (Bio-Rad). Samples were run on a 4-20% polyacrylamide gel for analysis.   
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3.4 Nucleic Acids show minimal rescue effect when agitated 
Previous studies have shown that TDP-43 readily aggregates when agitated 
(Johnson et al., 2009). It has also been determined that decreasing the salt concentration 
of the buffer will lead TDP-43 to aggregate. The addition of TG12 DNA to TDP-43 has 
been shown to suppress aggregation of the protein at room temperature (Sun et al., 2014).  
To test whether aggregation of TDP-43 could be prevented during agitation, 
several different nucleic acids were combined with the dimeric TDP-43 and vigorously 
shaken at 1400RPM in a thermomixer. All samples containing S48E-TDP-43 aggregated 
at 25°C with agitation as can be seen by the increase in turbidity starting at 30 min and 
spanning a time frame of 16 hours (Fig 17). This data is congruent with previous reports 
that TDP-43 is inherently aggregation prone. TDP-43, when supplemented with TG12  
(Fig. 18 G,J,M) and AUG12 (Fig 18 I,L,O) DNA and RNA, shows a slight lag in 
increasing turbidity compared with no DNA (Fig. 18A) and AC12 (Fig 18 H,K,N) controls 
(See Fig 18 A vs G,J,M, and O). This lag could account for suppression of aggregation by 
nucleic acid binding. Several controls including GFP, BSA, and nucleic acid only 
solutions did not aggregate under identical conditions (Fig 17 and 18).   
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Figure 17.  Aggregation of GFP-S48E-TDP-43 in vitro.  GFP-S48E-TDP-43 and 
GFP-S48E-TDP-43+ RNA/DNA variants were incubated at 25°C with agitation for 0-
960min in a buffer of 170mM NaCl, 36mM HEPES, and 3mM Me. Aggregation was 
determined by turbidity at 395nm. Nucleic acid in 1, 5, and 10 x stochiometric excess to 
TDP-43 protein. Values with error bars are means ±SD (n=2-3). RNA/DNA sequences 
in Table S5 in the appendix  
N
o
 D
N
A
1
:1
 T
G
1
:5
 T
G
1
:1
0
 T
G
1
:1
 A
C
1
:5
 A
C
1
:1
0
 A
C
1
:1
 A
U
G
1
:5
 A
U
G
1
:1
0
 A
U
G
G
F
P
T
G
 o
n
ly
 
A
C
 o
n
ly
 
A
U
G
 O
n
ly
 
B
S
A
B
u
ff
e
r
0 .0
0 .2
0 .4
T u rb id ity
S a m p le
A
b
s
o
r
b
a
n
c
e
 (
3
9
5
n
m
)
0  M in
3 0  M in
6 0  M in
9 0  M in
1 2 0  M in
9 6 0  M in
44 
 
  
Figure 18. Individual aggregation data of TDP-43 aggregation in vitro. Separated 
data from Figure 17 for better representation of turbidity. Absorbance is read at 396nm. 
Colors are consistent with Figure 17. Values are represented as mean ±SD (n=2-3) 
 
Figure 96.  Aggregation of S48E assessed by sedimentation analysis.  A) 
Fluorescence at 511nm take before and after aggregation of GFP-S48E-TDP43 and 
GFP-S48E-TDP-43 + RNA/DNA variants as in Figure 17.  B) Percent difference of 
before and after sample means ±SD (n=2-3)Figure 97. Individual aggregation data 
of TDP-43 aggregation in vitro. Separated data from Figure 17 for better 
representation of turbidity. Absorbance is read at 396nm. Colors are consistent with 
Figure 17. Values are represented as mean ±SD (n=2-3) 
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Fluorescence assays were used to assess the amount of TDP-43 protein in the 
pellet at TDP-43 “end-point” of aggregation. Similarly, we hypothesized that the change 
in GFP fluorescence in the supernatant would correspond to the amount of non-
aggregated TDP-43 still left in the supernatant. Visual comparisons of no-DNA added 
TDP-43 and 1:10 TDP-43 to TG12 show substantially increased fluorescence of 
supernatant with added nucleic acid (Fig. S3).  Using EGFP’s previously reported 
emission/absorbance spectrum (Kennis et al., 2004), the data obtained was in parallel to 
data received by turbidity measurements. Addition of TG12 and AUG12 DNA and RNA 
showed a change in fluorescence which is associated with aggregation (Fig 19).  
Addition of RNA/DNA does appear to substantially influence results however, 
statistical significance is lacking in results obtained to date. The results show no 
Figure 19.  Aggregation of S48E assessed by sedimentation analysis.                        
A) Fluorescence at 511nm take before and after aggregation of GFP-S48E-TDP43 and 
GFP-S48E-TDP-43 + RNA/DNA variants as in Figure 17.  B) Percent difference of 
before and after sample means ±SD (n=2-3) 
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conclusive evidence for correlation of attenuation of aggregation during agitation with 
the addition of a nucleic acid substrate.  
3.5 Cleaved protein visible in aggregates  
TDP-43 C-terminal truncations of 25kDa and 35kDa have been found in 
inclusions of patients with ALS and FTD (Arai et al., 2010). After 16 hours of agitation, 
analysis of GFP-S48E-TDP43 and GFP-S48E-TDP-43 + RNA/DNA variant samples 
were sedimented and supernatant removed from pellet. SDS-PAGE of supernatant and 
pellet species shows two species present, one at 75kDa and a smaller species at ~60kDa 
(Fig 20). All pellet species show bands at ~75kDa confirming the presence of TDP-43 in 
the pellets, probably aggregated. Lanes with the supernatant for the 1:1, 1:5, and 1:10 
TG12 DNA added species show faint bands increasing in concentration from 1 to 10 
suggesting that TDP-43 is present in the supernatant as well.  Lanes with AC12 added 
appear to be similar to that of the No DNA added with distinct bands at ~75kDa in pellet 
analysis and minimal to no band in the supernatants species. Lanes with AUG12 added are 
similar to the AC12 and No DNA with the exception of the 1:10 AUG12 which shows a 
band at ~75kDa in the supernatant fraction. These results conclude that addition of 
nucleic acid has a minimal effect on attenuation of aggregation when agitated for long 
periods of time (16 hours).  
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Figure 20.  Supernatant/ Pellet analysis of S48E aggregates after in vitro 
aggregation studies. After aggregation analysis of GFP-S48E-TDP43 and GFP-S48E-
TDP-43 + RNA/DNA variants samples were sedimented and supernatant removed from 
pellet. 10 µL of each sample was run on an SDS 4-20% polyacrylamide gel for analysis. 
Protein compared against Precision plus Protein Ladder (Bio-Rad)A) Samples 1-4. B) 
Samples 5-8. C) Samples 9-10. D) SDS-PAGE of purified GFP-S48E before agitation  
E) Table of sample names 
 
Figure 107.  Supernatant/ Pellet analysis of S48E aggregates after in vitro 
aggregation studies. After aggregation analysis of GFP-S48E-TDP43 and GFP-S48E-
TDP-43 + RNA/DNA variants samples were sedimented and supernatant removed from 
pellet. 10 µL of each sample was run on an SDS 4-20% polyacrylamide gel for analysis. 
Protein compared against Precision plus Protein Ladder (Bio-Rad)A) Samples 1-4. B) 
Samples 5-8. C) Samples 9-10. D) SDS-PAGE of purified GFP-S48E before agitation E) 
Table of sample names 
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CHAPTER 4: DISCUSSION AND SUMMARY 
TDP-43 is a 414 residue protein that is known to bind DNA and RNA, has been 
shown to repress HIV-1 transcription, and to regulate the splicing of the CFTR gene 
(Morimoto & Cuervo, 2009). TDP-43 has been found ubiquitinated, phosphorylated, and 
cleaved in inclusion bodies in brain tissue of patients with ALS and FTD (Neumann et 
al., 2006). Many researchers have undertaken investigating the structure of this protein in 
an effort to gain a understanding about how TDP-43 aggregates, however, the 
mechanisms by which TDP-43 aggregates in these disease pathologies is still unknown 
(Morgan & Orrell, 2016). 
Native TDP-43 exists as a dimer with a structured N-terminal domain, two RNA 
Recognition motifs, and a flexible C-terminal domain. Each of these domains play 
important roles in TDP-43’s structure and function and while the entire structure of TDP-
43 has yet to be resolved, much is known about the individual domains. The NTD of 
TDP-43 is known to facilitate dimer association in a head-tail-fashion through hydrogen 
bonds and electrostatic interactions (Afroz et al., 2017). A crystal structure of this domain 
has recently been published showing the NTD adopting both a ubiquitin- and axin-1-like 
fold (Afroz et al., 2017). TDP-43 contains two RRMs which have been resolved by 
crystallography and show the RRMs to bind UG/TG repeats with high specificity(Chiang 
et al., 2016; Furukawa et al., 2016; Kuo et al., 2009). The highly flexible CTD of TDP-43 
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is intrinsically aggregation prone and the majority of ALS disease associated mutations 
are in this region. Due to its highly disordered nature not as much is known about the 
structure of the CTD compared with the other domains. An NMR structure was resolved 
Figure 21. S48E Mutation. Mutation of serine 48 to glutamate depicted in a cartoon as a 
stick model with hydrogen bonding (red). When serine is mutated the hydrogen bond in 
the intermolecular interaction is lost. A) Normal intermolecular interaction with Ser48 
and Glu17. B) No hydrogen bond interaction when mutated to glutamate.  
50 
 
showing an alpha-helical segment of the CTD which is suspected to drive aggregation of 
the full length protein.  
Within each of these domains are notable mutations that affect TDP-43s structure 
and function. A phosphomimetic mutation in the NTD, where the serine at residue 48 is 
mutated to a glutamate, has been shown to disrupt intramolecular association of the dimer 
configuration (Fig. 21) (A. Wang et al., 2018). In the RRMs there are a series of 
phenylalanines that play and important role in RNA binding. When these phenylalanines 
are mutated to leucines RNA binding is abolished, disrupting the native function of this 
protein (Gopal et al., 2017). The C-terminal domain is home to a number of mutations 
that are involved in disease pathogenesis. One of these mutations, Q331K, is located in 
the α-helical segment of the domain. This mutation disrupts the α-helix and drives 
aggregation of the protein.  
TDP-43 is known as an RNA binding protein with preference for TG/UG rich 
sequences. Binding models suggest that when in proximity with nucleic acid the RRMs 
will bind ssDNA/RNA with a rapid on/off rate (Bhardwaj et al., 2013). TDP-43 remains 
soluble in the presence of RNA as can be demonstrated by studies where depletion of 
nuclear RNA by RNAse A generated aggregates (Huang et al., 2013). Previous work 
used these findings that RNA plays an important role in TDP-43 solubility and   
demonstrated the ability to attenuate aggregation with the addition of TG rich sequences 
(Sun et al., 2014). Our work tested the applicability of these findings to the S48E 
phosphomimetic mutant by looking at the ability of nucleic acid to mitigate aggregation 
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in agitation experiments. Full length TDP-43 is inherently aggregation prone and has 
been shown to aggregate upon agitation (Johnson et al., 2009).  
Due to its high aggregation tendencies, full length TDP-43 is difficult to purify in 
its monomeric form (A. Wang et al., 2018). Previous studies have reported the ability to 
purify their specific constructs using nickel affinity (Sun et al., 2014), GST columns  
(Kitamura et al., 2018), and size exclusion chromatography  (Johnson et al., 2009). We 
originally attempted to purify our protein construct using methods described by Sun el al. 
however, were not able to obtain a purified construct but rather a complex of proteins. 
We surmise that this could be a factor of using a different vector absent of a fusion 
construct, specifically one labeling a maltose binding protein (MBP) tag, which has been 
described in other studies to help solubilize the aggregation prone C terminal tail (A. 
Wang et al., 2018). Different purification strategies and adaptations from other studies 
that were able to purify monomeric TDP-43 were used. Differences between this study’s 
successful purification approach and the original purification are described in 
supplementary table 4 (Table S4).  
Due to the failure to produce a pure monomeric WT protein using conventional 
purification methods, a denaturing purification method using 6M urea was attempted. 
Lysis and subsequent column purification using a background of 6M urea was not able to 
be performed as no protein bound to the Ni/NTA column but instead eluted in the flow 
through (Fig S1). It is suspected that this occurred as a result of the urea unfolding the 
TDP-43 in such a way that the protein refolded and oligomerized creating an aggregate 
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with the buried affinity tag. This tag binds the protein to the column, gets buried within 
the hydrophobic core of the protein making the ligands inaccessible by the Ni/NTA resin. 
A second purification method where cells were lysed in the absence of urea then 
bound to the column and were washed off the column with a supplemented wash buffer 
containing 6M urea was also pursued. Elution profiles and SDS-PAGE gels identified the 
majority of protein being washed off in the presence of the 6M urea wash buffer with 
lower imidazole concentration (Fig. S2). This protein fraction was further analyzed via 
SEC and DLS and presented as an oligomer with a radius ≥10nm. Interestingly, other 
species can be observed on the elution profile of the denaturing purification during 
imidazole elution (Fig S.2, “elution 2”). Elution 2 was not used for analysis due to the 
majority of protein eluting in the first profile. However, it cannot be ruled out that the 
protein in elution 2 is the monomeric or dimeric TDP-43 species we were hoping to 
purify, as the protein is still present in this second species as observed by SDS-PAGE 
(Fig. 14).      
 Purification of a TDP-43 variant was accomplished using the phosphomimetic 
mutation described to disrupt dimer formation of the NTD of TDP-43 (A. Wang et al., 
2018). A crystal structure of the TDP-43 NTD dimer shows an intermolecular interaction 
of Ser48 on one strand of the dimer and hydrogen bonding with Glu17 on the other (Fig 
21) (Afroz et al., 2017). SEC purification and analysis of the GFP-S48E-TDP-43 
mutation resulted in two elution peaks. The first elution peak in the void volume of the 
column suggests the presence of aggregates and a second peak eluted at a retention time 
consistent with a protein whose molecular weight is similar to that of the TDP-43 dimer 
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(Fig. 15). DLS measurements confirmed the radius of the species eluted to be consistent 
with previous reports of the dimer formation at 5.3nm (Sun et al., 2014). 
 Addition of nucleic acid to the purified GFP-S48E-TDP-43 dimer in agitation 
experiments began to show a trend of slight delay in aggregation as determined by 
turbidity measurements. The results however are not conclusive because they are not 
statistically significant within 1σ. TDP-43 has previously been reported to have a 
specificity for UG/TG rich sequences but is also known to bind other nucleic acid 
sequences. There have been several reports that show TDP-43s inherent propensity to 
aggregate (Johnson et al., 2009). There have also been reports that prove nucleic acid’s 
ability to hinder aggregation of TDP-43 protein (Sun et al., 2014). However, to the best 
of our knowledge, there have been no reports on the addition of nucleic acid to TDP-43 
during agitation, mimicking the effects that may cause MND in CTE. Our results 
illustrate that addition of TG12 and AUG12 begin to show an effect of minimal mitigation 
of aggregation during agitation. While the effects are observable they are not as 
pronounced as was hypothesized and the experiments can be improved upon more to 
reach statistical significance for conclusive data. One possible explanation for the 
minimal mitigation effect is the presence of pre-formed, possibly terminally aggregated, 
aggregates in solution. TDP-43 has been reported to self-associate into aggregates in a 
time frame of 30 minutes at room temperature (Sun et al., 2014). An additional 
speculation for why the inhibitory effect is not so pronounced is that the vigorous shaking 
of solution isn’t allowing for nucleic acid to bind to the RRM. As was mentioned before, 
DNA binds and dissociates from the TDP-43 in a rather fast manner. The rapid agitation 
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of the protein/nucleic acid solution may account for faster dissociation or otherwise 
provide an environment that is not suitable for binding. The phosphomimetic mutation, 
S48E, could also contribute to the mitigated attenuation effects. There is no conclusive 
evidence that the S48E-TDP-43 is binding nucleic acid in our studies. Future work could 
utilize a gel shift assay in order to visualize binding activity with the mutation.  
 Fluorescence assays were used to observe the amount of protein remaining in the 
supernatant vs. the aggregate with the assumption that aggregated protein would localize 
in the pellet. These sedimentation analysis results observed the fluorescence of GFP in 
the supernatant with the hypothesis that large aggregates sedimented into the pellet 
fraction which non-aggregated TDP-43 remained in the supernatant. These fluorescence 
assays of the supernatant are congruent with turbidity results which tell us that the 
addition of nucleic acid with protein in agitation experiments has minimal attenuation 
effects. Rescue from agitation induced aggregation with the nucleic acid was even less 
pronounced in this fluorescence assay of supernatant vs. the pellet which could be an 
effect of the measurements being taken at the “end-point” (~16 hours) of agitation. 
Turbidity results indicated that even with the addition of nucleic acid, aggregates were 
still being formed. The data received from fluorescence assays report mostly complete 
aggregate formation of agitated samples. The presence of two species as resolved by 
SDS-PAGE of supernatant vs. pellet of the agitated samples agrees with the finding that 
TDP-43 is cleaved in aggregates.   
 Further work streamlining the methods by which the TDP-43 protein is subjected 
to agitation studies will be important in determining the effect by which nucleic acid may 
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attenuate aggregation during agitation. In addition, modification of the vector by adding a 
MBP tag as is described in other studies may assist in the purification of full length 
proteins that may be used in agitation experiments as well.  
Overall, we were not able to produce a purified monomeric species of WT protein 
using the methods described by previous studies, and our data suggest that urea 
denaturation does not produce a purified monomeric protein but rather a large, soluble 
oligomeric species. It can also be concluded that the addition of a phosphomimic mutant 
to the NTD of TDP-43 delays aggregation, perhaps disrupting self-association (A. Wang 
et al., 2018). Addition of nucleic acid to TDP-43 showed substantial decrease in 
aggregation propensity of species in heat stress environments in previous studies; 
however, the ability to mitigate aggregation while agitated was less pronounced in this 
study.   
56 
 
REFERENCES 
 
Afroz, T., Hock, E. M., Ernst, P., Foglieni, C., Jambeau, M., Gilhespy, L. A. B., … 
Polymenidou, M. (2017a). Functional and dynamic polymerization of the ALS-
linked protein TDP-43 antagonizes its pathologic aggregation. Nature 
Communications, 8(1), 1–14. https://doi.org/10.1038/s41467-017-00062-0 
Afroz, T., Hock, E. M., Ernst, P., Foglieni, C., Jambeau, M., Gilhespy, L. A. B., … 
Polymenidou, M. (2017b). Functional and dynamic polymerization of the ALS-
linked protein TDP-43 antagonizes its pathologic aggregation. Nature 
Communications, 8(1), 1–14. https://doi.org/10.1038/s41467-017-00062-0 
Aguzzi, A., & Calella, A. M. (2009). Prions: Protein Aggregation and Infectious 
Diseases. Physiological Reviews, 89(4), 1105–1152. 
https://doi.org/10.1152/physrev.00006.2009 
Arai, T., Hasegawa, M., Nonoka, T., Kametani, F., Yamashita, M., Hosokawa, M., … 
Akiyama, H. (2010). Phosphorylated and cleaved TDP-43 in ALS, FTLD and other 
neurodegenerative disorders and in cellular models of TDP-43 proteinopathy. 
Neuropathology, 30(2), 170–181. https://doi.org/10.1111/j.1440-1789.2009.01089.x 
Arnold, E. S., Ling, S.-C., Huelga, S. C., Lagier-Tourenne, C., Polymenidou, M., 
Ditsworth, D., … Cleveland, D. W. (2013). ALS-linked TDP-43 mutations produce 
aberrant RNA splicing and adult-onset motor neuron disease without aggregation or 
loss of nuclear TDP-43. Proceedings of the National Academy of Sciences, 110(8), 
E736–E745. https://doi.org/10.1073/pnas.1222809110 
Ayala, Y. M., Pantano, S., D’Ambrogio, A., Buratti, E., Brindisi, A., Marchetti, C., … 
Baralle, F. E. (2005). Human, Drosophila, and C. elegans TDP43: Nucleic acid 
binding properties and splicing regulatory function. Journal of Molecular Biology, 
348(3), 575–588. https://doi.org/10.1016/j.jmb.2005.02.038 
Bhardwaj, A., Myers, M. P., Buratti, E., & Baralle, F. E. (2013). Characterizing TDP-43 
interaction with its RNA targets. Nucleic Acids Research, 41(9), 5062–5074. 
https://doi.org/10.1093/nar/gkt189 
Bonafede, R., & Mariotti, R. (2017). ALS Pathogenesis and Therapeutic Approaches: 
The Role of Mesenchymal Stem Cells and Extracellular Vesicles. Frontiers in 
Cellular Neuroscience, 11(March), 1–16. https://doi.org/10.3389/fncel.2017.00080 
Borroni, B., Stanic, J., Verpelli, C., Mellone, M., Bonomi, E., Alberici, A., … Gardoni, F. 
(2017). Anti-AMPA GluA3 antibodies in Frontotemporal dementia: A new 
molecular target. Scientific Reports, 7(1), 1–10. https://doi.org/10.1038/s41598-017-
06117-y 
Brange, J., Havelund, S., & Hougaard, P. (1992). Chemical Stability of Insulin. 2. 
Formation of Higher Molecular Weight Transformation Products During Storage of 
Pharmaceutical Preparations. Pharmaceutical Research: An Official Journal of the 
American Association of Pharmaceutical Scientists. 
https://doi.org/10.1023/A:1015887001987 
Brown, R. H., & Al-Chalabi, A. (2017). Amyotrophic Lateral Sclerosis. New England 
Journal of Medicine, 377(2), 162–172. https://doi.org/10.1056/NEJMra1603471 
Budini, M., Romano, V., Quadri, Z., Buratti, E., & Baralle, F. E. (2015). TDP-43 loss of 
57 
 
cellular function through aggregation requires additional structural determinants 
beyond its C-terminal Q/N prion-like domain. Human Molecular Genetics, 24(1), 9–
20. https://doi.org/10.1093/hmg/ddu415 
Buratti, E., & Baralle, F. E. (2001). Characterization and Functional Implications of the 
RNA Binding Properties of Nuclear Factor TDP-43, a Novel Splicing Regulator of 
CFTR Exon 9. Journal of Biological Chemistry, 276(39), 36337–36343. 
https://doi.org/10.1074/jbc.M104236200 
Buratti, E., Dörk, T., Zuccato, E., Pagani, F., Romano, M., Baralle, F. E., … Green, M. 
(2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR 
exon 9 skipping. The EMBO Journal, 20(7), 1774–1784. 
https://doi.org/10.1093/emboj/20.7.1774 
Chang, C. ke, Wu, T. H., Wu, C. Y., Chiang, M. hui, Toh, E. K. W., Hsu, Y. C., … 
Huang, J. J. T. (2012). The N-terminus of TDP-43 promotes its oligomerization and 
enhances DNA binding affinity. Biochemical and Biophysical Research 
Communications, 425(2), 219–224. https://doi.org/10.1016/j.bbrc.2012.07.071 
Chapman, E. G., Moon, S. L., Wilusz, J., & Kieft, J. S. (2014). RNA structures that resist 
degradation by Xrn1 produce a pathogenic dengue virus RNA. ELife, 2014(3), 1–25. 
https://doi.org/10.7554/eLife.01892 
Chaturvedi, S. K., Siddiqi, M. K., Alam, P., & Khan, R. H. (2016). Protein misfolding 
and aggregation: Mechanism, factors and detection. Process Biochemistry, 51(9), 
1183–1192. https://doi.org/10.1016/j.procbio.2016.05.015 
Chi, E., Krishnan, S., & Kendrick, B. (2003). Roles of conformational stability and 
colloidal stability in the aggregation of recombinant human granulocyte colony‐
stimulating factor. Protein Science, 12, 903–913. 
https://doi.org/10.1110/ps.0235703.mer 
Chi, E. Y., Krishnan, S., Randolph, T. W., & Carpenter, J. F. (2003). Physical stability of 
proteins in aqueous solution: Mechanism and driving forces in nonnative protein 
aggregation. Pharmaceutical Research, 20(9), 1325–1336. 
https://doi.org/10.1023/A:1025771421906 
Chiang, C. H., Grauffel, C., Wu, L. S., Kuo, P. H., Doudeva, L. G., Lim, C., … Yuan, H. 
S. (2016). Structural analysis of disease-related TDP-43 D169G mutation: Linking 
enhanced stability and caspase cleavage efficiency to protein accumulation. 
Scientific Reports, 6(September 2015), 1–14. https://doi.org/10.1038/srep21581 
Chiti, F., & Dobson, C. M. (2006). Protein Misfolding, Functional Amyloid, and Human 
Disease. Annual Review of Biochemistry, 75(1), 333–366. 
https://doi.org/10.1146/annurev.biochem.75.101304.123901 
Choi, S. Il, Han, K. S., Kim, C. W., Ryu, K. S., Kim, B. H., Kim, K. H., … Seong, B. L. 
(2008). Protein solubility and folding enhancement by interaction with RNA. PLoS 
ONE, 3(7), 1–10. https://doi.org/10.1371/journal.pone.0002677 
Cléry, A., Blatter, M., & Allain, F. H. T. (2008). RNA recognition motifs: boring? Not 
quite. Current Opinion in Structural Biology, 18(3), 290–298. 
https://doi.org/10.1016/j.sbi.2008.04.002 
Cleveland, D. W., & Rothstein, J. D. (2001). From Charcot to Lou Gehrig. Nature 
Reviews Neuroscience, 2(November), 806–819. 
58 
 
Cohen, T. J., Hwang, A. W., Restrepo, C. R., Yuan, C., John, Q., & Lee, V. M. Y. 
(2015). Propensity. https://doi.org/10.1038/ncomms6845.An 
Conicella, A. E., Mittal, J., Fawzi, N. L., Biology, C., States, U., States, U., & States, U. 
(2017). HHS Public Access, 24(9), 1537–1549. 
https://doi.org/10.1016/j.str.2016.07.007.ALS 
D’Ambrogio, A., Buratti, E., Stuani, C., Guarnaccia, C., Romano, M., Ayala, Y. M., & 
Baralle, F. E. (2009). Functional mapping of the interaction between TDP-43 and 
hnRNP A2 in vivo. Nucleic Acids Research, 37(12), 4116–4126. 
https://doi.org/10.1093/nar/gkp342 
Day, R., Bennion, B. J., Ham, S., & Daggett, V. (2002). Increasing temperature 
accelerates protein unfolding without changing the pathway of unfolding. Journal of 
Molecular Biology, 322(1), 189–203. https://doi.org/10.1016/S0022-
2836(02)00672-1 
De Baets, G., Van Doorn, L., Rousseau, F., & Schymkowitz, J. (2015). Increased 
Aggregation Is More Frequently Associated to Human Disease-Associated 
Mutations Than to Neutral Polymorphisms. PLoS Computational Biology, 11(9), 1–
14. https://doi.org/10.1371/journal.pcbi.1004374 
Du, K., Karp, P. H., Ackerley, C., Zabner, J., Keshavjee, S., Cutz, E., & Yeger, H. 
(2015). Aggregates of mutant CFTR fragments in airway epithelial cells of CF 
lungs: New pathologic observations. Journal of Cystic Fibrosis, 14(2), 182–193. 
https://doi.org/10.1016/j.jcf.2014.09.012 
Fink, A. L. (1998). Protein aggregation: Folding aggregates, inclusion bodies and 
amyloid. Folding and Design, 3(1), 9–23. https://doi.org/10.1016/S1359-
0278(98)00002-9 
Furukawa, Y., Suzuki, Y., Fukuoka, M., Nagasawa, K., Nakagome, K., Shimizu, H., … 
Akiyama, S. (2016). A molecular mechanism realizing sequence-specific 
recognition of nucleic acids by TDP-43. Scientific Reports, 6(September 2015), 1–
12. https://doi.org/10.1038/srep20576 
Gambotto, A., Dworacki, G., Cicinnati, V., Kenniston, T., Steitz, J., Tü Ting, T., … 
Deleo, A. (2000). Immunogenicity of enhanced green fluorescent protein (EGFP) in 
BALB/c mice: identification of an H2-K d -restricted CTL epitope. Gene Therapy, 
7, 2036–2040. Retrieved from 
https://search.proquest.com/openview/eed3bb534d1f8c190ddb47048ef91adb/1?pq-
origsite=gscholar&cbl=34384 
Gopal, P. P., Nirschl, J. J., Klinman, E., & Holzbaur, E. L. F. (2017). Amyotrophic lateral 
sclerosis-linked mutations increase the viscosity of liquid-like TDP-43 RNP 
granules in neurons. Proceedings of the National Academy of Sciences, 114(12), 
E2466–E2475. https://doi.org/10.1073/pnas.1614462114 
Griesbeck, O., Baird, G. S., Campbell, R. E., Zacharias, D. A., & Tsien, R. Y. (2001). 
Reducing the environmental sensitivity of yellow fluorescent protein. Mechanism 
and applications. Journal of Biological Chemistry, 276(31), 29188–29194. 
https://doi.org/10.1074/jbc.M102815200 
Guenther, E. L., Ge, P., Trinh, H., Sawaya, M. R., Cascio, D., Boyer, D. R., … 
Eisenberg, D. S. (2018). Atomic-level evidence for packing and positional amyloid 
59 
 
polymorphism by segment from TDP-43 RRM2. Nature Structural and Molecular 
Biology, 25(4), 311–319. https://doi.org/10.1038/s41594-018-0045-5 
Haass, C., & Neumann, M. (2016). Frontotemporal dementia: from molecular 
mechanisms to therapy. Journal of Neurochemistry, 138, 3–5. 
https://doi.org/10.1111/jnc.13619 
Hachiya, N. S., Kozuka, Y., & Kaneko, K. (2008). Mechanical stress and formation of 
protein aggregates in neurodegenerative disorders. Medical Hypotheses, 70(5), 
1034–1037. https://doi.org/10.1016/j.mehy.2007.06.043 
Hillgren, A., Lindgren, J., & Aldén, M. (2002). Protection mechanism of Tween 80 
during freeze-thawing of a model protein, LDH. International Journal of 
Pharmaceutics, 237(1–2), 57–69. https://doi.org/10.1016/S0378-5173(02)00021-2 
Höhfeld, J. (2017). Preserving protein function through reversible aggregation. Nature 
Cell Biology, 19, 1142. Retrieved from http://dx.doi.org/10.1038/ncb3620 
Huang, Y. C., Lin, K. F., He, R. Y., Tu, P. H., Koubek, J., Hsu, Y. C., & Huang, J. J. T. 
(2013). Inhibition of TDP-43 Aggregation by Nucleic Acid Binding. PLoS ONE, 
8(5). https://doi.org/10.1371/journal.pone.0064002 
Jiang, L. L., Che, M. X., Zhao, J., Zhou, C. J., Xie, M. Y., Li, H. Y., … Hu, H. Y. (2013). 
Structural transformation of the amyloidogenic core region of TDP-43 protein 
initiates its aggregation and cytoplasmic inclusion. Journal of Biological Chemistry, 
288(27), 19614–19624. https://doi.org/10.1074/jbc.M113.463828 
Johnson, B. S., Snead, D., Lee, J. J., McCaffery, J. M., Shorter, J., & Gitler, A. D. (2009). 
TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked 
mutations accelerate aggregation and increase toxicity. Journal of Biological 
Chemistry, 284(30), 20329–20339. https://doi.org/10.1074/jbc.M109.010264 
Kameoka, D., Masuzaki, E., Ueda, T., & Imoto, T. (2007). Effect of buffer species on the 
unfolding and the aggregation of humanized IgG. Journal of Biochemistry, 142(3), 
383–391. https://doi.org/10.1093/jb/mvm145 
Katayama, D. S., Nayar, R., Chou, D. K., Valente, J. J., Cooper, J., Henry, C. S., … 
Manning, M. C. (2006). Effect of buffer species on the thermally induced 
aggregation of interferon-tau. Journal of Pharmaceutical Sciences, 95(6), 1212–
1226. https://doi.org/10.1002/jps.20471 
Kennis, J. T. M., Larsen, D. S., van Stokkum, I. H. M., Vengris, M., van Thor, J. J., & 
van Grondelle, R. (2004). Uncovering the hidden ground state of green fluorescent 
protein. Proceedings of the National Academy of Sciences of the United States of 
America, 101(52), 17988–17993. https://doi.org/10.1073/pnas.0404262102 
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., … 
Zoing, M. C. (2011). Amyotrophic lateral sclerosis. The Lancet, 377(9769), 942–
955. https://doi.org/10.1016/S0140-6736(10)61156-7 
Kiese, S., Papppenberger, A., Friess, W., & Mahler, H. C. (2008). Shaken, not stirred: 
Mechanical stress testing of an IgG1 antibody. Journal of Pharmaceutical Sciences, 
97(10), 4347–4366. https://doi.org/10.1002/jps.21328 
Kitamura, A., Shibasaki, A., Takeda, K., Suno, R., & Kinjo, M. (2018). Analysis of the 
substrate recognition state of TDP-43 to single-stranded DNA using fluorescence 
correlation spectroscopy. Biochemistry and Biophysics Reports, 14(March), 58–63. 
60 
 
https://doi.org/10.1016/j.bbrep.2018.03.009 
Krielgaard, L., Jones, L. S., Randolph, T. W., Frokjaer, S., Flink, J. M., Manning, M. C., 
& Carpenter, J. F. (1998). Effect of tween 20 on freeze-thawing- and agitation-
induced aggregation of recombinant human factor XIII. Journal of Pharmaceutical 
Sciences, 87(12), 1597–1603. https://doi.org/10.1021/js980126i 
Krishnan, S., Chi, E. Y., Webb, J. N., Chang, B. S., Shan, D., Goldenberg, M., … 
Carpenter, J. F. (2002). Aggregation of granulocyte colony stimulating factor under 
physiological conditions: Characterization and thermodynamic inhibition. 
Biochemistry, 41(20), 6422–6431. https://doi.org/10.1021/bi012006m 
Kueltzo, L. A., Wang, W., Randolph, T. W., & Carpenter, J. F. (2008). Effects of solution 
conditions, processing parameters, and container materials on aggregation of a 
monoclonal antibody during freeze-thawing. Journal of Pharmaceutical Sciences, 
97(5), 1801–1812. https://doi.org/10.1002/jps.21110 
Kumar, S., Mary Thangakani, A., Nagarajan, R., Singh, S. K., Velmurugan, D., & 
Michael Gromiha, M. (2016). Autoimmune responses to soluble aggregates of 
amyloidogenic proteins involved in neurodegenerative diseases: Overlapping 
aggregation prone and autoimmunogenic regions. Scientific Reports, 6(October 
2015), 1–13. https://doi.org/10.1038/srep22258 
Kuo, P. H., Chiang, C. H., Wang, Y. T., Doudeva, L. G., & Yuan, H. S. (2014). The 
crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition 
for UG- and TG-rich nucleic acids. Nucleic Acids Research, 42(7), 4712–4722. 
https://doi.org/10.1093/nar/gkt1407 
Kuo, P. H., Doudeva, L. G., Wang, Y. T., Shen, C. K. J., & Yuan, H. S. (2009). 
Structural insights into TDP-43 in nucleic-acid binding and domain interactions. 
Nucleic Acids Research, 37(6), 1799–1808. https://doi.org/10.1093/nar/gkp013 
Landsman, D. (1992). RNP-1, an RNA-binding motif is conserved in the DNA-binding 
cold shock domain. Nucleic Acids Research, 20(11), 2861–2864. 
https://doi.org/10.1093/nar/20.11.2861 
Lange, A., Mills, R. E., Lange, C. J., Stewart, M., Devine, S. E., & Corbett, A. H. (2007). 
Classical nuclear localization signals: Definition, function, and interaction with 
importin α. Journal of Biological Chemistry, 282(8), 5101–5105. 
https://doi.org/10.1074/jbc.R600026200 
Lee E. Goldstein, Andrew M. Fisher, Chad A. Tagge, Xiao-Lei Zhang, L., Velisek, John 
A. Sullivan, Chirag Upreti, Jonathan M. Kracht, Maria Ericsson, M. W., 
Wojnarowicz, Cezar J. Goletiani, Giorgi M. Maglakelidze, Noel Casey, J. A., 
Moncaster, Olga Minaeva, Robert D. Moir, Christopher J. Nowinski8, R. A., Stern2, 
8, Robert C. Cantu8, 9, James Geiling, Jan K. Blusztajn, B. L. W., Tsuneya Ikezu, 
Thor D. Stein, Andrew E. Budson, Neil W. Kowall, D., … Cleveland, Rudolph E. 
Tanzi, Patric K. Stanton,  and A. C. M. (2012). Chronic Traumatic Encephalopathy 
in Blast-Exposed Military Veterans and a Blast Neurotrauma Mouse Model. Science 
Translational Medicine. https://doi.org/10.1126/scitranslmed.3003716 
Lim, L., Wei, Y., Lu, Y., & Song, J. (2016). ALS-Causing Mutations Significantly 
Perturb the Self-Assembly and Interaction with Nucleic Acid of the Intrinsically 
Disordered Prion-Like Domain of TDP-43. PLoS Biology, 14(1), 1–35. 
61 
 
https://doi.org/10.1371/journal.pbio.1002338 
Mackenzie, I. R. A., & Neumann, M. (2016). Molecular neuropathology of 
frontotemporal dementia: insights into disease mechanisms from postmortem 
studies. Journal of Neurochemistry, 138, 54–70. https://doi.org/10.1111/jnc.13588 
Mahler, H. C., Müller, R., Frieß, W., Delille, A., & Matheus, S. (2005). Induction and 
analysis of aggregates in a liquid IgG1-antibody formulation. European Journal of 
Pharmaceutics and Biopharmaceutics, 59(3), 407–417. 
https://doi.org/10.1016/j.ejpb.2004.12.004 
Maris, C., Dominguez, C., & Allain, F. H. T. (2005). The RNA recognition motif, a 
plastic RNA-binding platform to regulate post-transcriptional gene expression. 
FEBS Journal, 272(9), 2118–2131. https://doi.org/10.1111/j.1742-
4658.2005.04653.x 
Martland, H. S. (1928). Punch drunk. Journal of the American Medical Association, 
91(15), 1103–1107. https://doi.org/10.1001/jama.1928.02700150029009 
Mckee, A. C., Cantu, R. C., Nowinski, C. J., Hedley-whyte, T., Gavett, B. E., Budson, A. 
E., … Stern, R. A. (2009). Chronic Traumatic Encephalopathy in Athletes: 
Progrsesive Tauopathy following Repetitive Head Injury. Journal of 
Neuropathology and Experimental Neurology, 68(7), 709–735. 
https://doi.org/10.1097/NEN.0b013e3181a9d503.Chronic 
McKee, A., & Gavett, B. (2010). TDP-43 proteinopathy and motor neuron disease in 
chronic traumatic encephalopathy. Journal of …, 69(9), 918–929. 
https://doi.org/10.1097/NEN.0b013e3181ee7d85.TDP-43 
Miyazaki, Y., Mizumoto, K., Dey, G., Kudo, T., Perrino, J., Chen, L. C., … Wandless, T. 
J. (2016). A method to rapidly create protein aggregates in living cells. Nature 
Communications, 7(May), 1–7. https://doi.org/10.1038/ncomms11689 
Mompeán, M., Buratti, E., Guarnaccia, C., Brito, R. M. M., Chakrabartty, A., Baralle, F. 
E., & Laurents, D. V. (2014). Structural characterization of the minimal segment of 
TDP-43 competent for aggregation. Archives of Biochemistry and Biophysics, 545, 
53–62. https://doi.org/10.1016/j.abb.2014.01.007 
Mompeán, M., Hervás, R., Xu, Y., Tran, T. H., Guarnaccia, C., Buratti, E., … Laurents, 
D. V. (2015). Structural Evidence of Amyloid Fibril Formation in the Putative 
Aggregation Domain of TDP-43. Journal of Physical Chemistry Letters, 6(13), 
2608–2615. https://doi.org/10.1021/acs.jpclett.5b00918 
Mompean, M., Romano, V., Pantoja-Uceda, D., Stuani, C., Baralle, F. E., Buratti, E., & 
Laurents, D. V. (2016). The TDP-43 N-terminal domain structure at high resolution. 
The FEBS Journal, 283(7), 1242–1260. https://doi.org/10.1111/febs.13651 
Mompeán, M., Romano, V., Pantoja-Uceda, D., Stuani, C., Baralle, F. E., Buratti, E., & 
Laurents, D. V. (2017). Point mutations in the N-terminal domain of transactive 
response DNA-binding protein 43 kDa (TDP-43) compromise its stability, 
dimerization, and functions. Journal of Biological Chemistry, 292(28), 11992–
12006. https://doi.org/10.1074/jbc.M117.775965 
Morgan, S., & Orrell, R. W. (2016). Pathogenesis of amyotrophic lateral sclerosis. British 
Medical Bulletin, 119(1), 87–97. https://doi.org/10.1093/bmb/ldw026 
Morimoto, R. I., & Cuervo, A. M. (2009). Protein homeostasis and aging: Taking care of 
62 
 
proteins from the cradle to the grave. Journals of Gerontology - Series A Biological 
Sciences and Medical Sciences, 64(2), 167–170. 
https://doi.org/10.1093/gerona/gln071 
Neumann, M., Sampathu, D. M., & Kwong, L. K. (2006). Ubiquitinated TDP-43 in 
frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 
314(5796), 130–133. https://doi.org/10.1126/science.1134108 
Ou, S. H., Wu, F., Harrich, D., García-Martínez, L. F., Gaynor, R. B., Garcia-Martinez, 
L., & Gaynor, R. B. (1995). Cloning and characterization of a novel cellular protein, 
TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence 
motifs. Journal of Virology, 69(6), 3584–3596. 
Philo, J. S., & Arakawa, T. (2009). Mechanisms of protein aggregation. Current 
Pharmaceutical Biotechnology, 10(4), 348–351. 
https://doi.org/10.2174/138920109788488932 
Prasad, A., Sivalingam, V., Bharathi, V., Girdhar, A., & Patel, B. K. (2018). The 
amyloidogenicity of a C-terminal region of TDP-43 implicated in Amyotrophic 
Lateral Sclerosis can be affected by anions, acetylation and homodimerization. 
Biochimie, 150, 76–87. https://doi.org/10.1016/j.biochi.2018.05.003 
Puvenna, V., Engeler, M., Banjara, M., Brennan, C., Schreiber, P., Dadas, A., … Janigro, 
D. (2016). Is phosphorylated tau unique to chronic traumatic encephalopathy? 
Phosphorylated tau in epileptic brain and chronic traumatic encephalopathy. Brain 
Research, 1630, 225–240. https://doi.org/10.1016/j.brainres.2015.11.007 
Ratti, A., & Buratti, E. (2016). Physiological functions and pathobiology of TDP-43 and 
FUS/TLS proteins. Journal of Neurochemistry, 138, 95–111. 
https://doi.org/10.1111/jnc.13625 
Ross, C. A., & Poirier, M. A. (2004). Protein aggregation and neurodegenerative disease. 
Nature Medicine, 10(7), S10. https://doi.org/10.1038/nm1066 
Rubinsztein, D. C. (2006). The roles of intracellular protein-degradation pathways in 
neurodegeneration. Nature, 443(7113), 780–786. 
https://doi.org/10.1038/nature05291 
Scheper, G. C., Van Der Knaap, M. S., & Proud, C. G. (2007). Translation matters: 
Protein synthesis defects in inherited disease. Nature Reviews Genetics, 8(9), 711–
723. https://doi.org/10.1038/nrg2142 
Scotter, E. L., Chen, H. J., & Shaw, C. E. (2015). TDP-43 Proteinopathy and ALS: 
Insights into Disease Mechanisms and Therapeutic Targets. Neurotherapeutics, 
12(2), 352–363. https://doi.org/10.1007/s13311-015-0338-x 
Shihong Li,’ Christian Schoneich,  and R. T. B. (1995). Chemical Instability of Protein P 
harm aceu t ica Is : Mechanisms of Oxidation and Strategies for Stabilization, 48, 
490–500. 
Stein, T. D., Alvarez, V. E., Mckee, A. C., & Traumatic, C. (2015). Concussion in 
Chronic Traumatic Encephalopathy. Curr Pain Headache Rep, 19(10). 
https://doi.org/10.1007/s11916-015-0522-z.Concussion 
Strambini, G. B., & Gonnelli, M. (2007). Protein stability in ice. Biophysical Journal, 
92(6), 2131–2138. https://doi.org/10.1529/biophysj.106.099531 
Sun, Y., Arslan, P. E., Won, A., Yip, C. M., & Chakrabartty, A. (2014). Binding of TDP-
63 
 
43 to the 3′UTR of Its Cognate mRNA Enhances Its Solubility. Biochemistry, 
53(37), 5885–5894. https://doi.org/10.1021/bi500617x 
Sun, Y., & Chakrabartty, A. (2017). Phase to Phase with TDP-43. Biochemistry, 56(6), 
809–823. https://doi.org/10.1021/acs.biochem.6b01088 
Treuheit, M. J., Kosky, A. a, & Brems, D. N. (2002). Inverse Relationship of Protein 
Concentration and Aggregation, 19(4). 
Van Buren, N., Rehder, D., Gadgil, H., Matsumura, M., & Jacob, J. (2009). Elucidation 
of two major aggregation pathways in an IgG2 antibody. Journal of Pharmaceutical 
Sciences, 98(9), 3013–3030. https://doi.org/10.1002/jps.21514 
Wang, A., Conicella, A. E., Schmidt, H. B., Martin, E. W., Rhoads, S. N., Reeb, A. N., 
… Fawzi, N. L. (2018). A single N‐terminal phosphomimic disrupts TDP‐43 
polymerization, phase separation, and RNA splicing. The EMBO Journal, e97452. 
https://doi.org/10.15252/embj.201797452 
Wang, W. (2005). Protein aggregation and its inhibition in biopharmaceutics. 
International Journal of Pharmaceutics, 289(1–2), 1–30. 
https://doi.org/10.1016/j.ijpharm.2004.11.014 
Wang, W., Nema, S., & Teagarden, D. (2010). Protein aggregation-Pathways and 
influencing factors. International Journal of Pharmaceutics, 390(2), 89–99. 
https://doi.org/10.1016/j.ijpharm.2010.02.025 
Westerlund, I., von Heijne, G., & Emanuelsson, O. (2009). LumenP-A neural network 
predictor for protein localization in the thylakoid lumen. Protein Science, 12(10), 
2360–2366. https://doi.org/10.1110/ps.0306003 
Woollacott, I. O. C., & Rohrer, J. D. (2016). The clinical spectrum of sporadic and 
familial forms of frontotemporal dementia. Journal of Neurochemistry, 138, 6–31. 
https://doi.org/10.1111/jnc.13654 
Yang-hartwich, Y., Bingham, J., Garofalo, F., Alvero, A. B., & Mor, G. (2015). 
Apoptosis and Cancer, 1219, 75–86. https://doi.org/10.1007/978-1-4939-1661-0 
Yang, C., Tan, W., Whittle, C., Qiu, L., Cao, L., Akbarian, S., & Xu, Z. (2010). The C-
terminal TDP-43 fragments have a high aggregation propensity and harm neurons 
by a dominant-negative mechanism. PLoS ONE, 5(12). 
https://doi.org/10.1371/journal.pone.0015878 
Zhang, Y. J., Caulfield, T., Xu, Y. F., Gendron, T. F., Hubbard, J., Stetler, C., … 
Petrucelli, L. (2013). The dual functions of the extreme N-terminus of TDP-43 in 
regulating its biological activity and inclusion formation. Human Molecular 
Genetics, 22(15), 3112–3122. https://doi.org/10.1093/hmg/ddt166 
 
 
64 
 
APPENDIX  
Supplemental Information 
 
Figure S1. Nickle affinity chromatogram of a denaturing urea purification with WT 
TDP-43. First urea purification attempt reveals no binding to the column. mAu of 
sample presented in teal. %B (mixture of lysis wash and elution wash) presented in 
green. 
Figure S2. Nickel affinity chromatogram of modified denaturing urea 
purification. Modified purification method (Materials and Methods) succeeded in 
binding recombinant protein vector and washing off the Ni/NTA column.    
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Figure S3. Visual Fluorescence Assay. Visual comparison of fluorescence intensity of 
GFP-TDP-43 samples with and without TG12 DNA. A) Before in vitro aggregation study 
of GFP-TDP-43 No DNA B) Before in vitro aggregation study of GFP-TDP-43 + TG12 
DNA C) After in vitro aggregation study of GFP-TDP-43 No DNA D) After in vitro 
aggregation study of GFP-TDP-43 + TG12 DNA. Green arrow identifies pellet after 
centrifugation.  
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LIC Primer Name Primer Sequence 5'-3' 
Forward Primer 
TACTTCCAATCCAATGCAATGTCTGAATATATTCGGGT
AACCG 
Reverse Primer 
1GFP 
TTATCCAACTTCCAATGTTATTACATTCCCCAGCCAGA
AGAC 
Reverse Primer 
mCitrine 
CTCCCACTACCAATGCCCATTCCCCAGCCAGAAGACTT
AG 
  
 
 
 
 
 
 
 
 
 
Name Nucleic Acid Sequence 
TG12 TGTGTGTGTGTGTGTGTGTGTGTG 
AC12 ACACACACACACACACACACACAC 
AUG12 GUGUGAAUGAAU 
 
 
 
 
 
 
 
 
 
Primer Name  Oligonucleotides 
T7 + AUG12 F TAATACGACTCACTATAGGTGTGAATGAAT 
T7 + AUG12 R ATTCATTCACACCTATAGTGAGTCGTATTA 
Table S1. Primers for LIC Cloning  
Figure S5. Primers for AUG12 RNA. Primers designed to create an AUG12 RNA 
containing a T7 sequence for transcription. 
Table S2. Primers for AUG12 RNA. Primers designed to create an AUG12 RNA 
Table S3. Sequences of DNA/RNA for in vitro aggregation 
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Table S4. Comparison of previous experiments and my experimental method.  
